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ABSTRACT 
 
This study demonstrates the various aspects of host immune response to Yersinia 
pestis. Y. pestis, the causative agent plague is mainly a rodent pathogen but is 
usually transmitted to humans via infected flea bite. After transmission to 
mammalian hosts, Y. pestis evades the host innate immune response and develops 
a systemic infection. Mast cells are recognized as the powerful sentinel cells 
responsible for controlling the early responses to a disease. We sought to 
determine whether mast cells are involved in the early innate immune response to 
Y. pestis and thus blocking mast cell degranulation would alter the outcome of 
infection. Mast cells in resistant young B10.T(6R) mice were depleted by use of 
anti-c-kit (ACK2) antibodies during Y. pestis infection. Our results demonstrated 
that Y. pestis infected anti-C kit treated mice showed lower survival rate than Y. 
pestis infected control mice suggesting mast cells are involved in early innate 
immune responses to Y. pestis. The other study is focused to understand the 
difference in the outcome of infection induced by endemic KIM5 and pandemic 
CO92 strains of Y. pestis. Both of these Yersinia strains have functional Type 
Three Secretion Systems (T3SS), which secretes effector molecules like Yersinia 
outer proteins (Yops) into the host cytosol to modulate the host immune response. 
KIM5 and CO92 strains express different isoforms of one of the Yop effectors, 
YopJ, which has been shown to inhibit NF-κB and MAPK activation in 
	  xi	  
mammalian cells. The YopJ isoform in Y. pestis KIM5 has two amino acid 
substitutions, F177L and K206E, which are not present in YopJ proteins of Y. 
pestis CO92. We show that young B10.T (6R) mice that are resistant to the KIM5 
strain (LD50 of 14,000 CFUs) were susceptible to the CO92 strain (LD50 of 17 
CFUs). A set of KIM5 isogenic strains expressing various YopJ isoforms allowed 
a demonstration that amino acid differences in YopJ were largely responsible for 
the increased virulence of the pandemic strain, CO92 in the B10.T (6R) mice.  
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CHAPTER I 
INTRODUCTION 
Yersinia pestis pathogenesis 
The genus Yersinia, belonging to the Enterobacteriaceae family consists of eleven 
species, of which three species are pathogenic to humans: Yersinia enterocolitica, 
Yersinia pseudotuberculosis and Yersinia pestis (180). The former two bacteria are 
enteropathogens transmitted by contaminated food and water causing gastroenteritis. The 
third pathogen Y. pestis is the causative agent of bubonic, pneumonic and septicemic 
plague. Plague is transmitted via bite of an infected flea. 
Plague in the Past 
Plague has been one of the deadliest diseases in the world with recorded death toll of 200 
million people (62) and resulting in three major pandemics. The first pandemic was the 
Justinian Plague (541 A.D to 544 A.D) originated in Pelusium, Egypt after spreading 
from Ethiopia. It quickly spread through the Middle East and the Mediterranean Basin 
(200). Subsequent outbreaks from 558 A.D to 640 A.D resulted in the distribution of the 
disease in North Africa, Europe, central and Southern Asia and Arabia. Taken together, a 
death toll between 15-40% for specific locales and epidemics have been ventured but it is 
estimated that from 541 A.D to 700 A.D there was a total population loss of 60% (200).
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The start of second pandemic occurred in Sicily, Italy in 1347 probably from the steppes 
of central Asia via trade route. The first epidemic (1347 A.D to 1351 A.D) was referred 
to as Black Death and resulted in death of 17 to 28 million Europeans representing 
population loss of 30 to 40% (148, 260). Despite the high mortality rates, the most 
important effects of the Black Death epidemic resulted from the relentless epidemic 
cycles.  Although the second pandemic was responsible for reducing majority of human 
population, it led to accelerate great changes in the social, economic and political 
development leading to implementation of policies, which brought changes in clinical 
research, medicine and public health regulations. 
The third pandemic started in the Yünnan Province of China in the year 1855 and spread 
to the southern coast of China. It reached Hong Kong and Canton in 1894 and Bombay in 
1898 and finally spread to Africa, Europe, Hawaii, North America and South America via 
steamships (34). In India alone plague was killing 12.5 million people between 1898 and 
1918. Overtime, human plague cases have declined due to effective public health 
measures and advent of antibiotics in the 1950s.  
Working independently, both Alexandre Yersin and Shibasaburo Kitasato were able to 
isolate the plague organism from the third plague pandemic. Initially, Kitasato was 
credited for the discovery, however Yersin Bacillus more accurately fits the current 
description of plague bacillus and Yersin used plague antiserum to cure a plague patient 
in 1896 (180). 
Plague in the Present 
Historically, plague is classified as the problem of the past. Since the plague bacillus is 
endemic in a variety of wildlife rodent species worldwide, it remains a current threat. 
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Two outbreaks of plague in Western India in 1994 followed by another outbreak in 2004 
in Northern India resulted in the deaths of millions (161). Over the years there was a 
major shift in cases from Asia to Africa. The 3 most endemic countries are Madagascar, 
the Democratic Republic of Congo and Peru. Madagascar alone accounted for 30% 
human cases worldwide from 2004 to 2009. From 2007 to 2011, bubonic plague 
accounted for 86.6% of suspected cases, while pneumonic and undocumented cases 
accounted for 9.4% and 4% respectively (10). World Health Organization (WHO) 
reported 783 cases of bubonic plague cases, including 126 deaths in 2013(Figure 1). 
 
 
 
Plague into the future 
Plague is difficult to eradicate because it is widespread in wildlife rodent reservoirs. 
Therefore there is a critical need to understand how humans can be affected by the 
dynamics of these wildlife reservoirs. Plague outbreak in North America and central Asia 
Figure 1. Reported Plague cases by country 2000-2009 
http://www.cdc.gov/plague/maps/  
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rodents and their risk to humans is affected by climate (71, 177) . Recent data from 
Kazakhstan shows that warmer springs and wetter summers increase the frequency of 
plague in its main host, the great gerbil (220). Such climatic conditions have shown to 
exist during the second and third pandemic. Although plague human cases reported are 
low in recent times, the threat to humanity cannot be ignored due to inherent 
communicability, rapid spread and high mortality state of the disease if left untreated. 
Also the ability of Y. pestis to acquire antibiotic resistance plasmid under natural 
conditions probably during its transit in the flea midgut is of alarm (84, 96, 102)  . Recent 
observation of the presence of multi drug resistant plasmids similar to those acquired by 
Y. pestis, in a variety of enterobacteria isolated from retail meat products in the United 
States is of great concern (247). The presence of multi resistant strains of Y. pestis would 
represent a major threat to human health. Finally, the fact that plague has been 
weaponised throughout history from catapulting corpses over city walls to dropping 
infected fleas from airplanes to refined modern aerosolization of the bacteria, has led us 
consider Y. pestis as a biological weapon threat (109, 119) . Due to the high mortality rate 
and rapid transmission of the bacteria from one person to another Y. pestis is considered 
by Center for Disease Control (CDC) as Category A agents along with anthrax, Botulism, 
Small Pox, Tularemia and Viral hemorrhagic fever. 
Epidemiology of Yersinia pestis 
Alexandre Yersin was the first person to correlate between rats and plague. Masanori 
Ogata and Paul-Louis Simond independently discovered the role of fleas in transmission 
of plague during the Indian epidemic in 1897 (180). Although plague is primarily a 
zoonotic disease affecting rodents but humans become incidental hosts to the disease 
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(Figure 2). Transmission between rodents is associated with fleas. The oriental rat flea 
Xenopsylla cheopis is the classic vector for plague. Fleas obtain Y. pestis from feeding 
0.03-0.5 µl of infected blood meal (104). A bacteremia of 104 CFU/ml will ensure 
ingestion of 300 Y. pestis organisms. The bacteria are cleared from some fleas but they 
multiply in the midgut of others. Two days post infected blood meal, the flea stomach or 
midgut display clusters of brown spots containing Y. pestis. These clusters then develop 
into solid dark brown masses containing the bacteria, fibrinoid like substances and hemin, 
which spreads throughout the stomach into the proventriculus and esophagus (13, 14). 
The proventriculus connects the esophagus to the stomach and also prevents regurgitation 
during a meal. Between 3 and 9 days post infected meal, the solid dark brown mass 
containing the bacteria blocks the proventriculus eventually preventing the ingested blood 
to reach the stomach (111). As a result when the flea next feeds, the blood sucked from 
the rodent is unable to reach the stomach of the fleas, instead the blood gets mixed with 
the bacilli present in the solid masses in the proventriculus and regurgitated into the 
mammalian host when the feeding attempt is terminated (111). While not all blocked 
fleas are responsible for transmission of the bacteria into a mammalian host, blockage is 
an important process ensuring transmission; unblocked fleas are rare in transmitting 
plague (32, 42).  
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The fate of the blocked flea is death due to starvation or dehydration. Due to lower 
temperature in the flea midgut (26°C), Y. pestis released from the fleas are unable to 
produce Fraction 1 capsule like antigen (F1) or any of the low calcium response stimulon 
(LCRS) components and are readily phagocytized by polymorphonuclear leukocytes 
(PMN) or macrophages. Cells phagocytized by PMNs are killed, while those 
phagocytized by macrophages survive intracellularly and develop resistance to 
phagocytosis. In a mammalian host at 37°C, by 3h, bacterial cells are resistant to 
phagocytosis by PMNs but not by monocytes. After 3 to 5 h, cells are resistant to uptake 
Figure 2: Plague Transmission Cycle (Used with permission)	   (180): Human to 
human transmission: By droplets (pneumonic) or by fleas (bubonic). Enzootic plague. 
Resistant hosts maintain a low profile, stable rodent-flea infection cycle, e.g., voles 
and deer mice. Epizootic plague. Sensitive or moderately resistant hosts are infected 
by fleas or by ingestion, resulting in a highly visible die-off, e.g., rats, prairie dogs, 
rock squirrels. Solid lines with arrows: direct route of transmission; dashed line with 
arrow: occasional route of transmission; dotted line with arrows: rare route of 
transmission 
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by both phagocytes i.e, PMNs and macrophages (14, 43) . The expression of F1 capsular 
antigen and various LCRS components by the bacteria contributes resistance to 
phagocytosis by the host phagocytes. Y. pestis released into the extracellular 
compartments then spread systemically to spleen and liver. 
The current scenario suggests that Y. pestis spread from the site of infected fleabite to 
regional lymph nodes resulting in swelling of the lymph nodes (called buboes). From the 
lymph nodes the organism spreads into the liver and spleen via bloodstream. For effective 
transmission in nature development of bacteremia of sufficient quantity and duration is 
essential. Infection of flea via the blood of an infected rodent completes the cycle. (180) 
An important aspect of host-parasite interaction is that the parasite will develop minimum 
symptoms in hosts to ensure their survival and dissemination. The enzootic maintenance 
cycle allows Y. pestis to thrive endemically in nature. The domestic black rat Rattus 
rattus or the brown sewer rats Rattus norvegicus are the primary host for the flea vectors 
(35). Currently, the role of black rats in plague epidemics in medieval Europe is debated 
upon. Investigators challenge that black rats were rare and the cold climatic conditions 
across Europe would not allow the black rats to survive (107). Climatic conditions and 
trade routes across Europe from Asia might be responsible for spreading the epidemic in 
Medieval Europe (204). In North America, the primary flea vector is Oropsylla montana, 
which transfers the bacteria to the California ground squirrels (Spermophilus beechyii) 
and rock squirrels (Spermophilus variegatus). Chipmunks, Tamias senex and T. 
quadrimaculatu has shown to have high seroprevalence for Y. pestis (214). As Prairie 
dogs are the primary food source for black-footed ferrets, it is hypothesized that plague 
exists in both enzootic and epizootic forms within prairie dogs. There is a cyclic die-off 
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of prairie dogs  (Cynomys spp.) that have an impact on black-footed ferret (Mustela 
nigripes) survival (145). 
Clinical Manifestations of Y. pestis 
Clinically Plague is present in three distinct forms in humans: bubonic, 
pneumonic, and septicemic. The different clinical form of plague depends on the route of 
infection and how bacteria disseminate throughout the body. 
Bubonic Plague 
The most common form of Y. pestis infection is bubonic plague. The usual 
symptoms includes fever, chills, headache and swollen lymph nodes (buboes, a 
characteristics sign of bubonic plague) within 2 to 6 days of contact with the organism 
either by flea-bite or by exposure of open wounds to infected animals. Gastrointestinal 
symptoms like nausea, vomiting, and diarrhea are common (108, 236) . At the initial site 
of an infection skin lesions may develop infrequently. Sometimes soreness in the affected 
lymph nodes will precede swelling. Depending on the site of the initial infection any of 
the lymph nodes areas can be involved: buboes are usually found in the inguinal and 
femoral regions but also occur in other nodes (34, 49) . Patients with bubonic plague are 
also characterized by bacteremia and secondary plague septicemia. Studies shows that 
blood culture colony ranges from <10 to 4 X 107/ml. Patients with colony counts greater 
than 100/ml have a high fatality rate. 
Septicemic Plague 
The second form of Y. pestis infection is septicemic plague. The two different 
forms of septicemic plague are primary and secondary. Primary septicemic plague occurs 
when the bacteria enter the host blood stream directly and patients with primary 
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septicemic plague are usually characterized by positive blood culture for the bacteria but 
no lymphadenopathy (206). Secondary septicemic plague develops when Y. pestis 
colonizes other areas (lymph nodes) before entering the blood stream. Symptoms 
developing due to primary and secondary septicemic plague include fever, chills, 
headache, and malaise. These symptoms are very similar to the symptoms observed 
during Gram-negative bacteria induced septicemia. The mortality rate is very high 
ranging from 30-50%. Such a high mortality rate may be because of antibiotics used to 
treat undifferentiated sepsis are not effective against Y. pestis (108). 
Pneumonic Plague 
The third and most rare form of Y. pestis infection is pneumonic plague. 
Pneumonic plague is the most deadly form of Y. pestis infection with 100% mortality rate 
with or without treatment. Pneumonic plague is the only form of plague that can spread 
from human to human. The two forms of pneumonic plague are primary and secondary.  
Primary pneumonic Plague develops via respiratory droplets through close 
contact with the infected individual. The incubation period of primary pneumonic Plague 
is 1-3 days (35). The bacteria colonize the lungs and induce a flu-like illness that rapidly 
progresses to an overwhelming pneumonia with severe cough and bloody sputum. 
Secondary pneumonic plague develops when Y. pestis either migrates from the 
lymph nodes (bubonic plague) or from blood (septicemic plague) to the lungs 
establishing a pneumonic infection. 
Diagnosis and Treatment 
To diagnose plague, sputum, blood samples and aspirates from the buboes can be used in 
the laboratory. A unique characteristic of Y. pestis is the bipolar staining and 
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pleomorphism. From bubo aspirates, Wright-Giemsa or Wayson stains will reveal the 
“safety pin” bipolar staining of Y. pestis (35). To isolate colonies from sputum samples 
Yersinia specific cefsulodin-irgasan-novobiocin (CIN) agar can be used (193). Recently, 
Y. pestis specific medium was developed containing combination of bile salts, irgasan 
and low concentrations of crystal violet to inhibit the growth of most other bacterial 
species (20). Y. pestis F1 antigen is detected by a rapid high specificity antigen detection 
test in clinical specimens from sputum, bubo aspirate and cerebrospinal fluid (46). Serum 
specimens containing seroconversions of four-fold or greater titers against Y. pestis F1 
antigen can also be used as a diagnostic test (109).  
 Traditionally, streptomycin has been considered the most effective treatment for 
plague (35). However, streptomycin is a bacteriolytic antimicrobial agent (180). The 
release of endotoxic products from lysed bacterial cells could escalate the chance of 
systemic shock in a Y. pestis-infected individual. Doxycycline, tetracyclines, third-
generation cephalasporins and quinolones are other alternative antimicrobials used to 
treat plague (186). Use of different treatment regimen depends on the different stage of 
disease development. 
            In 1995 two separate antibiotic resistant strains of Y. pestis were isolated (84). 
The first isolate, Y. pestis (17/95) was resistant to all recommended antimicrobial agents 
against the plague, except trimethoprim whereas the second isolate, Y. pestis (16/95) 
exhibited high levels of resistance to streptomycin. In both cases, resistance was carried 
on a conjugative plasmid capable of conjugation between Y. pestis strains and E. coli.  It 
has been speculated that conjugation of the resistance plasmids may have taken place 
within a human or rat host. 
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Characteristics of Yersinia pestis 
 The genus Yersinia belonging to the Enterobacteriaceae family is a gram-
negative, non-motile, non-spore forming coccobacillus. The organism is capable of 
growth between 4°C and 40°C but the optimal growth conditions for Y. pestis are 
temperatures between 28°C and 30°C (180). Growth is slow generally requiring 24 - 48 h 
for colony formation at 28-30°C, however the generation time of Y. pestis in defined 
media is 90 minutes. At all temperatures, Y. pestis requires L-methionine, L-
phenylalanine, L-isoleucine, L-valine and glycine for growth. Growth restriction 
decreases the chances of long-term survival outside of the host. However, mammalian 
blood is rich in these organic nutrients and Y. pestis thrives within the host (26). Also the 
temperature shift from 26°C to 37°C in the mammalian system alters gene expression and 
leads to the production of virulence factors expressed by Y. pestis. 
Yersinia pestis, like other Gram-negative bacteria, has lipopolysaccharide (LPS) 
in its outer membrane. The LPS of Y. pestis is characterized as rough because it lacks an 
O- group side chain due to a mutation in the O-antigen gene cluster (187). The bacteria 
do not have a typical capsule but do form a carbohydrate-protein envelope, termed 
capsular antigen or fraction 1(F1) at temperatures above 33°C. 
The genome size of Y. pestis is ~4,380 ± 135 kb (139). The three plasmids found 
in wildtype isolates of Y. pestis are pCD1, pMT1 and pPCP1. pCD1 is a shared plasmid 
between pathogenic Yersinia species, while pMT1 and pPCP1 are unique to Y. pestis.   
During in vitro growth at 37°C, in low calcium concentrations, the replication and 
gene expression is altered in Y. pestis. Growth restriction at 37°C in the absence of 
calcium results from shutdown of stable net RNA synthesis, inhibition of protein 
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synthesis and a decrease in adenylate energy charge (259).  Simultaneously, virulence 
factors encoded on pCD1 are produced and regulated by this “low calcium response” 
phenomenon. 
Species Evolution  
The closest evolutionary relative of Y. pestis is a clone derived from Y. 
pseudotuberculosis and is believed to have emerged as a separate species between 1,500 - 
20,000 years ago (4). Genome sequence analysis of virulent Y. pestis CO92 (176) and 
KIM10 (Kurdistan Iran Man) (58), shows that many of the virulence factors were 
acquired from its parental strain, Y. pseudotuberculosis. Genomic-fluidity and horizontal 
gene transfer from a Y. pestis-progenitor strain diverged from Y. pseudotuberculosis 
resulted in acquisition of only two virulence plasmids and 32 additional genes (38). 
Numerous pseudogenes present in Y. pestis are still functional in Y. 
pseudotuberculosis (45). Several of the pseudogenes encodes for factors important in 
adherence and invasion of eukaryotic cells in enteropathogenic species of Yersinia. For 
example adhesion and invasion molecules important in the pathology of Y. 
psuedotuberculosis, but are non-functional in Y. pestis are YadA and InvA (180). Other 
gene products identified in Y. pestis that are analogous to YadA and InvA in Y. 
pseudotuberculosis are YadBC (80) and YapE (127) that may aid in bacterial 
colonization. The loss of these genes may play a role in the unique and recent 
evolutionary adaption of arthropod-borne transmission in Y. pestis and the difference in 
disease pathology. 
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Biovars 
Based on Y. pestis ability to ferment glycerol and reduce nitrate to nitrite, there 
are three biovars of Y. pestis: Antiqua, Medievalis, and Orientalis.  Antiqua is positive for 
both characteristics (186), Medievalis ferments glycerol but is unable to reduce nitrates 
and Orientalis cannot ferment glycerol but can reduce nitrate (3). Recently, these biovars 
were associated to regional outbreaks with spread of disease in pandemics (186). Based 
on synonymous single neucleotide polymorphisms (SNPs) Achtman et al. analyzed 156 
strains of Y. pestis and constructed a phylogenetic tree (3) that correlated with earlier 
biochemical and historical work.  Probing for Y. pestis DNA and protein signatures from 
ancient mass graves that are historically considered to be the result of outbreaks have 
further confirmed the etiology of plague pandemics. Y. pestis was accountable for the 
Justinian plague and 1st pandemic (60). Samples from purported plague burial sites from 
the time period of the 2nd pandemic also associated Y. pestis with the outbreak (61). 
Interestingly, all of the isolates linked to the above studies appear to have originated from 
the biovar Orientalis. Another study using genotyping found evidence that plague spread 
through Europe in two distinct upsurges (98). One upsurge was caused by biovar 
Orientalis, while the other was caused by biovar Medievalis. A non-human pathogenic 
biovar Microtus was identified recently (266). 
Virulence Factors  
The most proficient vector for transmission of plague, Xenopsylla cheopis, the 
classic vector for transmission of plague shows poor competence in the uptake of Y. 
pestis from an infected host (138).  For an infection to occur in the flea, Approximately 
104 bacteria are required. However, the LD50 for most susceptible mammals can be as 
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low as 10 bacteria (180). For proper transmission of plague in mammalian hosts, a 
threshold of 106 CFU/ml are required. Such high bacteremia can be lethal to the 
mammalian host due to endotoxic shock. Y. pestis has adapted numerous virulence 
functions to ensure both proper colonization within the midgut of the flea and to allow for 
efficient vegetative growth within the mammalian host without causing host death. 
Plasminogen activator (Pla protease): Initially, it was believed that the 
coagulase activity of the pPCP1-encoded plasminogen activator (Pla) was responsible for 
the blockage of the proventriculus and bacterial aggregation in the flea (42). The 
coagulase model suggests that Y. pestis are enveloped and actively multiply in a fibrin 
clot found within the bloodmeal of a flea due to the coagulase activity of Pla. However 
recent studies show that the coagulase activity of Pla is weak and Pla mutant are still able 
to form aggregates that block the X. cheopis flea midgut (101). Transmission electron 
microscopy (TEM) of the Y. pestis infected flea proventriculus revealed that the bacteria 
were tightly packed together and were surrounded by an extracellular matrix (101). Y. 
pestis was forming a biofilm within the proventriculus and this was giving rise to 
aggregates and a “blocked” flea. At present, the more accepted model is the Biofilm 
Model of Proventricular Infection (110), which suggests that the temperature shift from 
host (37°C) to flea (26°C) induces the expression of Y. pestis genes specific for biofilm 
formation. Pla also aids in propagation of bacteria from the subcutaneous site into 
circulation.  In vitro studies show that Pla of Y. pestis cleaves host plasminogen to 
plasmin; following disruption of the extracellular matrix (ECM), and Pla can bind 
directly to the ECM, letting the bacteria adhere to the ECM (128). Abolition of the 
proteolytic activity of Pla results in decreased virulence in mice infected via peripheral 
	   15	  
routes (215) as the bacteria are unable to spread from the site of infection to the lymph 
node and eventually systemically. However, Pla mutants of Y. pestis are still fully 
virulent if injected intravenously into mice (206). Pla protease is vital for bacterial 
colonization, but not dissemination as suggested by studies in a murine model of primary 
pneumonic plague (126). Also a Pla mutant of Y. pestis if injected intraperitoneally along 
with the injection of iron enhances the virulence of Y.pestis suggesting that rather than 
serving as a nutrient, iron inactivates a host factor that compensates for the mutation.  Pla 
protease is also essential for the invasion of epithelial cells in vitro (55) and may play a 
role as a Y. pestis adhesin or invasin.  
Iron assimilation and pigmentation: Iron is an essential nutrient that is chelated 
by mammalian proteins making it less available to invading pathogens. Y. pestis requires 
iron for growth and infection. The 102 kb pigmentation (pgm) locus in the chromosome 
contains a high pathogenicity island that carries 11 genes encoding for proteins involved 
in siderophore synthesis. The siderophore, yersiniabactin, is involved in iron acquisition 
during infection(18). Pigmented (Pgm+) cells of Y. pestis do not produce a pigment but 
adsorb large amounts of excess hemin that causes the formation of the pigmented 
colonies at 26°C but not 37°C, and are virulent in mice. All clinical isolates contain the 
pgm locus (28) and strains lacking this locus (pgm-) are attenuated during infection. 
Supplementing mice with inorganic iron during mammalian infection restores virulence, 
demonstrating the important role of iron-acquisition to plague virulence (205). Studies in 
the pulmonary challenge model restored virulence after supplementing with inorganic 
iron (129). Bacteria are able to colonize the lungs and thrive, but there is still a lack of 
pulmonary damage and inflammation.  
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Murine toxin: Y. pestis has the pMT1 plasmid, which is absent from Y. 
pseudotuberculosis and Y. enterocolitica. pMT1 is a 110-kb plasmid. One gene product 
of pMT1 is the murine toxin (MT). MT is a phospholipase D that is required for 
colonization of the flea gut (25). MT is also lethal to mice and rats but not other animals 
like chimpanzees, monkeys, pigs and rabbits (156). However, it is not essential for 
virulence in a mouse model (103, 199). 
Fraction 1 capsule: Another virulence factor specific to Y. pestis that is encoded 
on the pMT1 plasmid is the 15.5 kDa F1 capsule-like antigen (F1). The four genes that 
are located within the caf1 (capsule antigen F1) operon are caf1, caf1A, caf1M, and 
caf1R. All except caf1R are required for assembly of a complete Caf1 (F1) subunit (135). 
At 37°C but not 26°C, F1 forms a large gel-like structure or envelope around the 
bacterium (180). Expression of F1 antigen is correlated with resistance to phagocytosis 
by monocytes. A decrease in ability to phagocytize bacteria was observed when murine 
macrophages were infected with Y. pestis expressing wildtype F1 compared to 
macrophages infected with mutant F1 (63).  Numerous animal models show that F1 is not 
necessary for virulence (250) and a F1- strain has been isolated from a human case of 
plague (254). The genetic background of mouse strains used in F1 pathogenicity studies 
may also contribute to the differences seen in virulence between F1 and F1 mutant Y. 
pestis (240). A decrease in virulence was observed in a F1 mutant of Y. pestis in BALB/c 
mice compared to C57BL/6 mice. 
pH 6 Antigen: Another virulence factor of Y. pestis is the chromosomally 
encoded fimbrial structure PsaA (pH 6 Ag) that is anti-phagocytic in nature (106).  PsaA 
is synthesized at 37°C in acidic media, agglutinates erythrocytes, recognized as a 
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fimbriae structures and released from Y. pestis after internalization by phagocytes (133). 
This may contribute to why Y. pestis is resistant to phagocytosis after internalization and 
release by macrophages (43). Also, PsaA- Y. pestis is attenuated in an intra venous mouse 
model of infection (134). 
Lipopolysaccharide (LPS): Y. pestis, like other Gram-negative bacteria, has 
lipopolysaccharide (LPS) in its outer membrane. LPS is a ligand for Toll-like- Receptor 
(TLR4), one kind of pattern recognition receptor (PRR). Y. pestis synthesizes two forms 
of LPS; tetra- and hexa-acylated based on temperature (157). At 26˚C, bacteria grown in 
the flea gut produce a hexa-acylated LPS, which can trigger TLR4-mediated immune 
signaling to induce pro-inflammatory cytokines such as TNF-ɑ, IL-1β, IL-6 and IL-8. But 
after the temperature transition from the flea gut (26˚C) to mammalian host (37˚C), Y. 
pestis synthesizes tetra-acylated LPS, which is non-stimulatory for TLR4 mediated 
immune signaling, as well as resistant to complement mediated lysis and phagocytosis 
(64, 157).  
Serum resistance: Y. pestis is resistant to complement mediated lysis regardless 
if grown at 26°C or 37°C (11). Resistance to complement mediated-lysis may be 
responsible for the survival of the bacteria in both flea and mammals. Synthesis of Ail 
outer membrane protein is one of the components of resistance to complement-mediated 
killing. This type of serum mediated resistance is most prominent in infection models of 
guinea pigs, rabbits, sheep, goats, and humans, but normal mouse serum has no 
bactericidal properties against Y. pestis and a Δail strain is still fully virulent in a mouse 
model of infection (16). This suggests that the contribution of Ail protein to Y. pestis 
virulence is species-specific.  
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Type III secretion system (T3SS): One of the factors contributing to virulence is 
the complex type III secretion system (T3SS), which delivers multiple effector proteins to 
the cytoplasm of host cells in contact with the bacteria (234). The T3SS is encoded by the 
plasmid pCD1, (CD stands for “calcium dependence”) which is a 70.5 kb plasmid. The 
T3SS delivers six Yersinia outer proteins (Yops) directly into the cytoplasm of host 
innate immune cells. Usually, the function of Yop translocation is to decrease phagocytic 
activity, cell paralysis, induce apoptosis, inhibit autophagy, and manipulate intracellular 
trafficking (159).  Together, these functions would result in suppression of a 
proinflammatory response to plague. This is demonstrated in a murine model of Y. pestis 
infection (168). Mice infected with pCD1 negative Y. pestis have a robust inflammatory 
response compared to mice infected with wildtype Y. pestis where there is little to no 
inflammatory response. The following section will cover, in detail, the T3SS effector 
proteins of Y. pestis and the reported mechanisms of host immune response manipulation 
(Figure 3). 
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Figure 3: Y. pestis resistance mechanism in response to innate immunity (Used with 
permission)	   (6). (A) Resistance mechanisms at the early stage of infection. The various 
LPS structures of Y. pestis during transition between flea and host temperatures make the 
bacteria resistant to the complement-mediated lysis and suppress the proinflammatory 
response. Simultaneously, the bacteria phagocytosed by macrophages proliferate and 
express different virulence determinants to act on host immune response. (B) Release of 
Y. pestis into the extracellular milieu. The bacteria released from macrophages have the 
ability to resist phagocytosis and can inhibit the production of proinflammatory 
cytokines, which also attenuate the host’s adaptive immunity.  
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The LcrV (also known as V-antigen) protein is a multifunctional protein 
associated with the tip of the injectisome needle complex (162). The LcrV protein 
interacts with the negative regulator LcrG and also associates with YopB/YopD to 
transport the effector molecule into the host cytoplasm (54). After being secreted into the 
environment, LcrV interacts with TLR2 and CD14 to stimulate the production of IL-10 
(210), which is an anti-inflammatory cytokine. IL-10 then suppresses the formation of 
various pro-inflammatory cytokines including TNF-α and IFN-ϒ as seen in Y. pestis 
infection studies both in vivo and in vitro (170). Soluble LcrV can be found in the blood 
of the infected host (79) and suppresses neutrophil chemotaxis independently of T3SS 
Yop translocation (248). In the absence of the receptor, LcrV can directly bind to human 
IFN-γ (89). This binding affinity appears to be unique to Yersinia as studies show that an 
LcrV homolog, PcrV (Pseudomonas aeruginosa-derived), does not bind to IFN-γ (89). 
Thus, LcrV results in an overall down regulation of a general inflammatory response. 
There are six effector proteins of the Yersinia-family T3SS that have been shown 
to modulate the host immune system: YopE, YopJ/YopP, YopM, YopH, YopT, and 
YpkA/YopO (234).  
            YopH is a protein tyrosine phosphatase. The major target of YopH is a focal 
adhesion molecule p130Cas .  YopH- mediated dephosphorylation of p130Cas leads to 
disruption in actin structures, including loss of focal adhesion and inhibition of 
phagocytosis. Other YopH targets include focal adhesion kinase (FAK), paxillin, Lck, 
Fyb and SKAP-HOM (50). Y. enterocolitca-derived YopH has also been shown to 
inactivate the phosphatidylinositol 3-kinase pathway (PI-3 kinase), that reduces the 
production of monocyte chemoattractant protein 1 (MCP1) (201). Bacterial strains 
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lacking YopH (CO92 ΔyopH) are avirulent in an intranasal and subcutaneous plague 
model (29) and are able to induce a host proinflammatory response (37).  Vaccination 
with live CO92 ΔyopH is also protective against subsequent plague challenge (29). These 
data suggests that the direct ability of YopH to downregulate a proinflammatory response 
that contributes to plague virulence. 
YopM is 46.2 kDa acidic protein that consists of leucine rich repeats (51) and is 
the effector protein that lacks catalytic activity. The targets of YopM were two kinases: 
ribosomal S6 protein kinase 1(RsK1) and protein kinase c-like 2(Prk2). YopM bind to α-
thrombin and inhibits thrombin-induced platelet aggregation (130). The contribution of 
YopM to plague virulence has been explored by infection with YopM mutant strains of Y. 
pestis.  YopM mutant strains are highly attenuated in virulence (117). Flow cytometric 
analysis of natural killer cells shows that there was a depletion of NK cells in the spleens 
and blood of Y. pestis KIM5 infected mice than mice infected with YopM mutant strain 
(117). YopM infected NK cells are defective to secrete interferon-gamma (IFN-Υ) and 
there are undetectable levels of IL-15R mRNA. For homeostasis and maintenance of host 
NK cell populations, interaction of IL-15 with IL-15R is important (116).  It is unclear 
how YopM downregulates IL-15R and whether that results in decrease in the number and 
function of NK cells during infection. Infection studies shows that YopM depletion of 
natural killer cells is organ-specific (257). Unexpectedly, antibody-mediated depletion of 
NK cells did not increase virulence of YopM mutant strains. Removal of neutrophils 
(Gr1+) did increase virulence of YopM mutant strains, suggesting that neutrophils and a 
subset of inflammatory monocytes helps to clear ΔyopM   Y. pestis (257) and neutrophils 
and monocytes may be a target of YopM during infection.  
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YopE is a GTPase activating protein targeting small RhoA-like G proteins, 
including RhoA, Rac1 and CDC42. YopE inhibits G proteins by inducing their GTPase 
activity. Cells infected by wild type Yersinia spp. undergo apoptosis, a process that does 
not induce any inflammatory mediators. However, in cells infected with YopE mutant 
strains, there is uptake of extracellular molecules and release of cytosolic proteins such as 
LDH, suggesting that YopE is involved in resealing pores made by the T3SS, thereby 
preventing leakage of cellular contents and stimulation of the host immune system. YopE 
also contributes to antiphagocytic activity (228). 
YopT is a cysteine protease found exclusively in Y. enterocolitica. Studies 
demonstrated that YopT functions by disrupting actin microfilaments during infection. 
(228).  
YpkA is a multidomain protein that functions as serine/threonine kinase. YpkA 
localizes to the cytoplasmic face of the plasma membrane in eukaryotic cells (185). It 
disrupts the actin cytoskeleton and contributes to the ability of Yersinia to resist 
phagocytosis by macrophages (228) 
            YopJ (YopP in Y. enterocolitica) is a 33 KDa protein that inhibits multiple MAPK 
signaling pathways and the NF-KB pathway (175). YopJ belongs to a family of cysteine 
proteases (53). Evidence suggests that YopJ functions as a deubiquitinase (224). YopJ 
also has acetyltransferase activity that acetylates serine and threonine residues important 
for activation of mitogen activated protein kinase (MAPK) kinase (MKKs) and IκB 
kinase complex (IκκB) pathways (152, 153, 163). The loss of cellular signaling events 
results in downregulation of various cytokines, chemokines and adhesion molecules. 
Down regulation of cytokines allows Yersinia to inhibit the recruitment and activation of 
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macrophages and neutrophils to the site of infection and thus evade the host 
inflammatory response (169). YopJ functions by binding to multiple members of MAPK 
kinase superfamily including MKKs and IkB kinase B (IKKB). In resting cells, NF-κB is 
bound to its inhibitor IκB and retained in the cytoplasm. IκB can be phosphorylated by 
IκB kinase, IKK. Following phosphorylation of IκB leads to its ubiquitination and 
degradation. NF-κB is then freed to enter the nucleus and affect transcription. YopJ 
acetylates IκB and thus prevents its phosphorylation. If phosphorylation of IκB is 
prevented, then IκB remains bound to NF-κB, thus blocking the NF-κB pathway (152). 
YopJ can also induce LPS-stimulated apoptosis in macrophages (197).  Apoptosis, or 
programmed cell death, is the organized disassembling of cellular structures and the lack 
of formation of a proinflammatory response (78). Bone marrow-derived macrophages 
with constitutive expression of an active inhibitor of NF-κB, inhibitor of κB kinase β 
(IKKß) are completely resistant to YopJ-dependent apoptosis, demonstrating that YopJ 
inhibits signaling upstream of IKKß (262). LPS activates apoptosis in macrophages by 
signaling via the adaptor protein Toll/IL-R domain-containing adaptor-inducing IFN-β 
(198). Together, LPS-activation can lead to anti- apoptotic signals through expression of 
the NF-kB-induced anti-apoptosis product, plasminogen activator inhibitor 2 (PAI-2) 
(95). During Gram-negative bacterial infections PAI-2 negatively regulates both 
apoptosis and caspase-1 induction and could act as a negative feedback loop to ensure an 
innate immune response without cell death. Yersinia species have adapted various modes 
to manipulate this system resulting in pro-apoptotic response without a strong induction 
of inflammation and thus evading the host immune response. 
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Pyroptosis is a form of programmed cell death that results in the proteolytic 
cleavage of the pro-IL-1β and -IL-18 by caspase-1 and secretion of the mature forms of 
these proinflammatory cytokines (78). YopJ can also inhibit caspase-1-dependent 
pyroptosis in activated macrophages (132). Naïve macrophages infected with Yersinia are 
targeted for apoptosis whereas activated macrophages undergo caspase-1-dependent 
pyroptosis (19). Allelic polymorphisms seen in YopJ isolates between species, and strains 
may explain marked difference in the levels of apoptosis and pyroptosis observed when 
macrophages are infected with Y. pestis. Y. pestis KIM5 encodes for an isoform of 
YopJKIM that stimulates higher levels of apoptosis and pyroptosis , and production of IL-
1β (132). YopJKIM has two amino acid substitutions (F177L, K206E), which are not 
present in YopJCO92 (132). Studies show that YopJKIM has a higher binding affinity to 
IKKβ and increased inhibition of NF-κB, when compared to YopJ from Y. pestis CO92 
and YopJ from Y. pseudotuberculosis (264). Human neutrophils are intrinsically resistant 
to YopJ-induced cell death	  (216). Activated-neutrophils can phagocytize and kill Y. pestis 
unlike macrophages wherein bacteria phagocytized survive intra cellularly (216). These 
findings show how complex and dynamic Y. pestis infection truly is and immune 
responses are different depending on infection routes and host. 
Vaccination and Protective Immunity Against the Plague 
In 1897, vaccination was used against plague (251). Heat-killed cultures of Y. 
pestis were used by Haffkine to treat plague patients. In 1970, Meyer et al. developed 
formalin-killed bacteria that were used as a plague vaccine (USP) which protected US 
military troops against exposure in Vietnam (251). However, whole-cell vaccines are 
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reactogenic (251) and might not contribute to protection against the pneumonic plague 
(251). 
The next approach to effective plague vaccines was to target known Y. pestis 
virulence factors. Mice and rats were protected against Y. pestis infection when 
vaccinated with the F1 capsular protein (15). Moreover, passive transfer from F1-
vaccinated rabbits was protective against pneumonic challenge (9). However, strains that 
lack F1 but cause disease were isolated, hence vaccination with just F1 would not protect 
against all strains of Y. pestis. 
A subunit vaccine consisting of F1 and the virulence protein LcrV provides 
greater protection in different routes of infection than either subunit by itself (194).  
Studies show that for both bubonic and pneumonic plague, (8) passive immunization with 
F1/LcrV antibodies is protective in infected mice. Serum titers of F1 and LcrV antibody 
correlate with protection in mouse and non-human primate models (249). However, the 
F1/LcrV vaccine is not completely protective against aerosolized infection in African 
green monkeys (194). Also Y. pestis strains may make a variant of LcrV that will not 
induce a protective immune response (184). LcrV has shown to upregulate IL-10 and 
sequester IFN-ϒ. LcrV that lacks the immunomodulatory domain is still protective and 
induces lower IL-10 production in vitro. All these factors should be taken into 
consideration while assembling a putative protein in a plague vaccine. The need for an 
effective vaccine that is protective for all routes of infection is enhanced by the potential 
of plague to be aerosolized and used as a biological weapon (186). 
TNF-α and IFN-ϒ are proinflammatory cytokines essential for protective 
immunity against plague. Lack of both TNF-α and IFN-γ throughout the disease 
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progression, with a slight spike of TNF-α just before death make it difficult to detect 
plague in early stages of Y. pestis infection (168). TNF-α and IFN-γ also play an 
important role in F1/LcrV antibody-mediated protection against intranasal challenge with 
fully virulent Y. pestis (137) and Y. pestis Δpgm (122). IL-17 is also important in 
protective immunity. After vaccination with a live-attenuated strain of Y. pestis there is 
an increase in IL-17 producing CD4+ T cells. Depletion of IL-17 decreases neutrophil 
migration and increases bacterial burden in this model (136). 
Adaptive immunity is also important in protection against plague. Adoptive 
transfer of CD4+ and CD8+ T cells from live attenuated Y. pestis vaccinated mice 
provides protection in µMT mice (184). DNA-based vaccine studies demonstrated that 
after LcrV vaccination, depletion of CD8+ T cells decreased protective immunity after 
challenge (188). Mouse dendritic cells (DEC-205/CD205+) targeted with a modified F1-
LcrV subunit vaccine primes CD4+ T cells, which induces the production of IFN-γ and is 
protective against subsequent challenge (59). Hence after vaccination or passive 
immunization, both cytokines and T cells are important in the protection against plague. 
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CHAPTER II 
ROLE OF MAST CELLS IN YERSINIA PESTIS INFECTION 
Introduction 
Although mast cells are known for their involvement in various inflammatory 
disorders, they are also recognized as the powerful sentinel cells responsible for 
controlling the early responses to a disease. Mast cells are distributed throughout the 
connective tissue of the body but tend to inhabit areas of confluence between host and 
external environment, such as the skin and mucosal barriers. Their preferential 
location at the host-environment interface and their innate capacity to release 
preformed mediators triggers the recruitment of pathogen clearing cells from the 
blood to the site of infection (2). Traditionally mast cells mediators are classified into 
two categories: preformed mediators that include proteases (chymases and tryptases), 
histamine, heparin, cytokines like TNF-α (123), and chemokines CXCL1/CXCL2 
(77) and those that are de novo synthesized when the cells are activated, which 
includes cytokines like IL-1, and eicosanoids as leukotrienes, prostaglandins and 
thromboxanes (85). Stimulation of mast cells leads to activation of Cl- channels in the 
plasma membrane, responsible for the release of mast cells mediators (195). The 
release of mast cells mediators is associated with diseases such as allergy, asthma, 
rheumatoid arthritis and chronic inflammatory diseases (120). 
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         In host defense mast cells utilize various mechanisms to detect pathogens. Mast 
cells can recognize pathogens directly through pattern recognition receptors (PRRs) 
such as TLRs, which are stimulated in response to conserved pathogen-associated 
molecular patterns (PAMPs). Type I fimbriae present on various enterobacteria and 
cell surface component of Mycobacterium tuberculosis binds to CD48 a GPI 
anchored protein present on mast cells (142, 164). Cross-linking of CD48 not only 
results in degranulation of mast cells but also results in uptake of the bacteria. Mast 
cell surface receptor FcRs include FcϒRII receptors and the high affinity receptor for 
IgE, FcεRI, both the receptors on mast cells can bind to IgG and IgE respectively and 
become sensitized to antigens that have been previously encountered by the host 
(115, 255). Subsequently mast cells can become activated resulting in degranulation 
following receptor cross-linking by polyvalent antigen (255). Interestingly, TLRs and 
FcεRI activation can have a synergistic effect on cytokine production by mast cells 
through the activation of mitogen activated protein kinases (MAPK) (189). Bacterial 
superantigens such as S.aureus protein A can also activate FcεRI signaling activating 
mast cells (90). Complement receptors C5aR can also activate mast cell degranulation 
(173). During infection mast cell activation is not always a result of contact with the 
infectious agent, their products or opsonized microbes; many stressed cells release 
danger signals or alarmins, which also serve as strong activators of mast cells (70, 
131). Anti microbial peptides, ATP, and IL-33 released by stressed cells can activate 
mast cells resulting in extensive degranulation (160).  
The innate immune function of mast cells located close to blood vessels include the 
release of histamine, TNF, proteases and vascular endothelial growth factor (VEGF) 
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attributes to increasing vascular permeability and edema at the site of infection (24, 
94, 207, 222). Chemokines like CCL11 and CXCL8 produced by mast cells recruits 
eosinophils and natural killer (NK) cells respectively (31). TNF and MCP6 derived 
from mast cells contribute to neutrophil recruitment in bacterial peritonitis models 
(105) and to inflamed tissues (21, 222). Additionally mast cells enhance mucus 
production by epithelial cells, immobilizing the pathogen and subsequently helping to 
clear pathogens from surfaces of gut, nasal mucosa and bladder (22). 
              Mast cells not only contribute to innate immune responses but also play a 
major role in triggering adaptive immune response. TNF released by mast cells 
upregulates expression of E-selectin by local endothelium, promoting the recruitment 
of monocyte derived dendritic cells (DCs) (208). CCL20 produced by mast cells 
contributes to the influx of DCs precursors from blood to the tissues. Thus, mast cells 
also aid in cell trafficking to draining lymph nodes (86). Moreover, mast cells 
themselves can present antigen to T cells. In a recent study, antigen pulsed mast cells 
were shown to stimulate CD8+ T cell activation, proliferation and production of T cell 
products such as IL-2 and granzyme B (219). Thus, mast cell and its mediators 
polarize the environmental milieu and form a bridge between the innate and adaptive 
immune response. 
          The contribution of mast cells to combat infection has been studied extensively. 
The protective role of mast cell derived TNF was first shown against Klebsiella 
pneumoniae infection (143) and against polymicrobial intra-abdominal sepsis (66). 
TNF released by mast cells recruit neutrophils to site of infection to clear the 
pathogen. A similar function of mast cells has been shown in other infection studies: 
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Pseudomonas aeruginosa infection of the mouse peritoneum (151), E. coli infection 
of the peritoneum and urinary tract (1), Helicobacter felis infection of the 
gastrointestinal tract (233) and Haemophilus influenza infection of the ear (65). Mast 
cells are also efficient against Gram-positive bacteria comprising Streptococcus 
pyogenes, Mycoplasma pulmonis (256) and Listeria monocytogenes (40). However, in 
the case of Salmonella infection there is suppression of mast cell degranulation. SptP 
(Salmonella Protein tyrosine Phosphatase) injected by the T3SS into the mast cell 
cytosol inhibited mast cell degranulation even after exposure to stimulants like 
IgE/antigen (47, 83, 113) .  
          Yersinia pestis, the etiological agent of plague is an obligate extracellular, 
gram-negative bacterium. Y. pestis encodes various virulence factors like F1 capsular 
antigen, plasminogen activator (Pla), LcrV, and the type III secretion system (T3SS). 
The T3SS secretes various effector molecules into the cytosol of host cells to 
modulate the host immune response. A previous study with LcrV has shown that 
LcrV induce IL-10 production, which suppresses the production of pro-inflammatory 
cytokines TNF-α and IFN-ϒ (248). For the spread of Y. pestis during infection, an 
anti-inflammatory environment is necessary. The inflammatory action of mast cells 
may counteract the immunosuppressive effect demonstrated by LcrV (210). 
Additionally, the inflammatory mediators released by mast cells also aid in recruiting 
neutrophils to the site of infection resulting in clearing of bacteria and contributing to 
host defense during Y. pestis infection. Due to highly susceptible plague models, 
immunological mechanisms involved in the Y. pestis host immune response are 
difficult to study.  
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           Cromolyn sodium has a short half-life and inhibits the release of inflammatory 
mediators from mast cells. Cromolyn blocks chloride channels, stabilizing mast cells 
membranes and inhibiting mast cell mediator release (165, 195) . Our lab has shown 
that blocking mast cell degranulation by use of cromolyn abolished resistance to 
infection in DQ8ɑβ transgenic mice in response to Y. pestis. We hypothesize that 
mast cells are involved in the early innate immune response to Y. pestis and thus 
blocking mast cell degranulation would alter the outcome of infection. To assay mast 
cell contributions in response to Y. pestis it would be ideal to use mast cell knockout 
mice. But, the most reliable knockout mouse is derived from the highly plague 
susceptible C57BL/6 strain. So developing a mast cell knock-down model during Y. 
pestis infection will be an alternative way to study the role of mast cells in plague. To 
determine the role of mast cells in Y. pestis infection, the mast cells in resistant young 
B10.T(6R) mice were depleted by use of anti-c-kit (ACK2) antibodies (12) during Y. 
pestis infection. Our results demonstrated that anti-C kit treated mice showed a lower 
survival rate than PBS treated mice. At day 3 there was higher load of bacteria in 
liver and spleen in PBS treated mice as compared to anti-c kit treated mice. 
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Material and Methods 
Mice 
Young (6 to 8 weeks of age) female B10.T (6R) mice (original breeding stock a gift from 
Dr. Chella David, Mayo Clinic and College of Medicine, Rochester, MN) were bred and 
maintained in a clean laminar flow containment area within the Center of Biological 
Research (CBR) at University of North Dakota. Young female B10.T (6R) mice were 
used for mortality studies. The University of North Dakota IACUC approved all animal 
studies. 
Yersinia pestis Infection 
Young B10.T (6R) mice were infected intravenously with Y. pestis KIM5. All strains 
were grown at 26˚C with shaking overnight in Heart Infusion broth (HIB; BD Difco) 
followed by subculture to 0.1 A620, and incubated at 26˚C with shaking to an A620 of 1.0. 
Bacteria were centrifuged at 3,220 X g for 5 min, washed twice in sterile phosphate 
buffered saline (PBS) and resuspended in PBS. For mortality studies, mice were 
monitored twice daily for survival for 21 days. The serial dilutions used for infection 
were plated on TBA (BD Difco, Sparks, MD) plates and colonies were counted after 2 d 
of incubation at 26˚C. 
Purification of Anti C Kit 2 antibody 
Anti-c kit antibody (ACK2) secreting cells were obtained from EB Brandt (Division of 
Allergy and Immunology and Department of Pediatrics, Cincinnati Children’s Hospital 
Medical Center, Cincinnati, Ohio, USA). ACK2 cells were maintained and the 
supernatant was collected. Antibodies were precipitated with saturated ammonium sulfate 
(SAS) solution. The precipitate was dissolved in PBS and dialyzed against PBS buffer. 
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The sample was then passed in a size-exclusion Sephacryl-S-200 column and the ACK2 
antibody was obtained. BCA assay or IgG ELISA quantified the monoclonal antibody 
obtained and western blotting was done to detect antibody against C-kit was present in 
the purified sample preparation. 
Depletion of mast cells 
For a single dose experiment, B10.T (6R) mice were injected intra-peritoneally (i.p.) with 
1.5 mg of anti-c-Kit antibody before infection. For multiple dose experiment, B10.T (6R) 
mice were injected intravenously with 1 mg of anti-c-Kit antibody before infection 
followed by 4 doses of 1 mg anti-c-Kit antibody every alternate day. Over 90% of mast 
cells were depleted with this procedure. Toluidine blue staining of ear tissue sections and 
flow cytometry of ear tissue samples were used to demonstrate depletion of mast cells in 
ACK2 treated mice. 
Identification of mast cells and neutrophils 
Ears were harvested from ACK2 treated mice and prepared for flow cytometry with 
slight changes (121). For flow cytometry, samples were centrifuged at 200 X g at room 
temperature. Cells were resuspended in PBS containing 0.1% BSA to a density of 1 X 
106 cells/ml. Cells were incubated for 1 h at 4°C in the dark with the following 
antibodies: PE-conjugated anti-FcεRI, FITC-conjugated anti-c-kit, PB-conjugated anti-
CD11b, and APC-conjugated anti Gr-1 (eBioscience). The excess antibody was washed 
by adding 1 ml of PBS containing 0.1% BSA and centrifuged for 5 min at 200 X g at 
4°C. The cell pellet was resuspended in 100 µl of PBS containing 0.1% BSA buffer. Mast 
cells were sorted and identified as c-Kit+FcERI+ cells. Several combinations of markers 
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were used to identify neutrophils (Gr1+ CD11b+). Flow cytometric analysis was 
performed on an LSR II flow cytometer (BD).  The histogram overlays were constructed 
using FlowJo (V.7.6.4). Ears were harvested and stained by toluidine blue to detect mast 
cells. 
Measurement of Bacterial Burden 
Livers and spleens were harvested at 3 d and 6 d from young infected B10.T(6R) 
mice and incubated in PBS containing 0.1% collagenase D for 1 h at 37°C. The challenge 
inoculum for Y. pestis was 1000 CFUs. All organs were homogenized by passage through 
70 µM pore-size nylon mesh cell strainers (Falcon-Corning Inc, Corning, NY). 
Homogenates were centrifuged at 3,200 X g at for 5 min. Pellets were resuspended in 
PBS containing 0.1% (vol/vol) Triton X-100 to lyse eukaryotic cells. Bacterial burden 
was determined by plating serial dilutions on TBA (BD Difco, Sparks, MD) plates. 
Statistical analysis 
Data in the Figures are expressed as the mean ± SEM. For mortality studies, statistical 
comparisons were carried out using Log-rank (Mantel-Cox) test in GraphPad Prism 
(version 5.0d, GraphPad Software Inc, La Jolla, CA). For two group comparisons, a two-
tailed unpaired t-test was used. For multiple groups, one way analysis of variance 
(ANOVA) with Bonferroni Multiple Comparison test as a post-test, a p value of <0.05 
was considered significant. 
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Results 
Depletion of mast cells 
Mast cells were depleted in B10.T(6R) mice by use of anti-c kit antibody (ACK2) (Table 
1 and Figure 4).  At 1 d post injection of ACK2 antibody, there was a decrease of 88.8% 
of mast cells in the ear tissue compared to the PBS treated mice. The decrease in mast 
cells was observed till day 3. Interestingly, there was an increase in the percentage of 
mast cells on day 5 compared to day 1 in ACK2 antibody treated mice (from 30 to 216). 
On day 5 in ACK2 antibody treated mice, mast cells are approximately similar in number 
to PBS treated mice. At day 7 mast cells are 96.6% suggesting that after anti-C-kit 
antibody treatment stops mast cells are recovered. 
Mast cells are required for effective anti Yersinia defense 
Mast cell depleted or control mice were infected intravenously (i.v) with 1.4 X 103 CFUs 
of Y. pestis. A decrease in survival was observed in mice receiving anti-c kit antibody 
compared to PBS treated infected mice (Figure 5). This suggests that mast cell depletion 
contributes to Y. pestis infection.  Mice that received multiple doses of anti-c kit antibody 
showed a decrease in survival compared to mice that received single dose of anti-c kit 
antibody (Figure 6).  
Differences in Bacterial Burden in anti-c kit antibody treated infected B10.T (6R) 
mice 
Eventually, Y. pestis infection spreads systemically throughout the visceral organs. 
Bacterial burdens were assessed in the spleens and livers of B10.T (6R) mice infected 
with 1000 CFUs of Y. pestis KIM5. At 3 d post-infection, KIM5 infected anti c-kit treated 
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mice B10.T (6R) mice had1.5 X 107 ± 1.3 X 107(mean ± standard error of mean [SEM]) 
CFU per spleen compared to 2.8 X 107 ± 1.7 X 107(mean ± SEM) CFU or 1.8 X 107 ± 4.5 
X 106 per spleen of isotype or PBS infected B10.T (6R) (Figure 6) Similarly, at 3 d post-
infection, KIM5 infected anti c-kit treated mice B10.T (6R) mice 1.3 X 106 ± 1.25 X 
106(mean ± standard error of mean [SEM]) CFU per liver compared to 3.5 X 106 ± 2.14 
X 106(mean ± SEM) CFU or 5.4 X 106 ± 1.54 X 106 per liver of isotype or PBS infected 
B10.T(6R) mice(Figure 7). There was no significant change in the bacterial burden in 
both liver and spleen at day 3 between the anti-c-kit treated antibody and PBS or isotype 
treated mice. However, by 6 d post-infection both the spleen and livers of anti-c kit 
treated mice had higher bacterial burden (4.6 X 106 and 9.5 X105 respectively) than PBS 
treated mice (0 and 1.75 X 105 respectively) (Figure 7 and 8). Higher bacterial burden in 
the anti-c kit treated B10.T(6R) mice at day 6 suggests that mast cells in young 
B10.T(6R) mice were important in anti-Yersinia defense in the host and mast cells may 
be responsible to successfully induce early immune responses to Y. pestis . 
Discussion 
Young inbred female B10.T (6R) mice show an increased resistance to Y. pestis than 
other outbred mice such as Swiss Webster mice. This phenomenon of resistance observed 
in B10.T (6R) mice allows us to explore other factors in a Y. pestis infection such as host 
responses to Y. pestis or Y. pestis virulence factors and their effect. The innate immune 
response recognizes invading pathogens, eliciting an immune response, which prevents 
the spread of invading pathogens while an adaptive immune response is generated. A 
significant feature of mast cells is their ability to rapidly respond to pathogens by 
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releasing preformed and de novo synthesized mediators, which helps to initiate and 
maintain pro-inflammatory responses. 
Traditionally mast cells are associated with IgE-mediated, Th2 responses to allergens but 
more recently they have been associated with host response during an infection. In vivo 
studies have shown that the role of mast cells in increased survival in infectious 
peritonitis, murine malaria, Citrobacter rodentium and Listeria monocytogenes infection 
(66, 82, 244). The decrease in survivability observed in these murine models is associated 
with the loss of mast cell function, either directly or indirectly. Various studies show that 
activated mast cells engulf pathogens and release pro-inflammatory mediators and 
chemotactic factors. One of the important pro-inflammatory cytokine released following 
mast cell activation is TNF-α. TNF-α is critical in initiating host defenses against 
pathogens, aids in generation of inflammatory reactions, activating endothelium, allowing 
the migration of immune cells into the site of infection and influencing dendritic cells and 
T cell recruitment, activation and function (166, 167, 223). 
Depletion of mast cells showed increased mortality in anti-c-kit antibody treated 
B10.T(6R) mice indicating that mast cell plays a pivotal role in defense against plague. 
However, the mechanism of how mast cells play a role to enhance host responses against 
plague has yet to be determined. Loss of mast cell degranulation may impair the ability of 
local immune cells, such as dendritic cells, neutrophils and T cells to be recruited to the 
site of infection, as cytokines and chemokines are not released. Apart from recruitment of 
immune cells to the site of infection, loss of mast cell degranulation also might affect 
dendritic cell maturation and presentation of antigen to T cells. Mast cell depletion might 
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also increase Y. pestis’s ability to evade the innate immune response by dampening the 
inflammatory reaction required by the host to suppress bacterial growth and spread. 
Mast cells are a multifunctional immune cells that act as a bridge between the innate and 
adaptive immune system. One-way mast cells act as a bridge between innate and adaptive 
immunity is to function as an antigen-presenting cell. MHC class I and class II molecules 
are expressed on the surface of mast cells (192). Mecheri et.al demonstrated that mast 
cells pulsed with antigen in vitro and injected into BALB/c mice were able to activate T 
cells to induce antibody response (235). Upon infection or in the presence of TNF-α or 
IFN-ϒ mast cells express MHC class II molecules. Exosomes are vesicles that express 
MHC class II molecules and are released into the extracellular milieu (211). In vivo mast 
cell derived exosomes have demonstrated the ability to induce maturation of dendritic 
cells allowing stimulation of T cells and initiation of adaptive immune responses (212). 
Mast cells exert their effects on lymphocytes by direct cell-cell contact, or the release of 
exosomes. Whether naïve mast cells stimulate lymphocyte function in vivo is yet to be 
studied. However it has been shown that mast cells are activated in the periphery and 
migrate to draining lymph nodes where they interact and activate lymphocytes (86, 238). 
These data suggest that a role of mast cells is triggering adaptive immune responses. 
Previous results demonstrated that cromolyn administration blocked mast cell 
degranulation, which showed the importance of mast cells in Y. pestis infection, 
indicating that the increased resistance might be partially due to mast cell. For the host to 
survive inflammatory immune responses is important against Y. pestis infection. Y. pestis  
has developed various tactics to down regulate host inflammatory responses. Our results 
demonstrated the importance of mast cells in a Y. pestis infection that by depleting mast 
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cells from resistant B10.T(6R) mice exacerbated the disease. Increased bacterial burden 
in anti-c-kit treated antibody than PBS treated mice demonstrated that mast cells play an 
important role in early host defense against Y. pestis. B10.T(6R) mice are compromised 
in the ability to mobilize neutrophils to the site of infection due to absence of mast cells. 
This result of increased bacterial growth in the spleen and liver of KIM5 infected B10.T 
(6R) mice during the later stages of Y. pestis infection. These results correlate with other 
studies showing the role of mast cells in infection and validate results obtained lately in 
mast cell reconstituted W/Wv mice (67). 
In conclusion, these results suggest that mast cells play a role in early anti-Yersinia host 
responses. In a contest between the host and pathogen, survival of the host depends on 
the ability of the host to induce a robust attack on the pathogen. Due to the presence of 
mast cells in the body tissues, mast cells are likely to be the first inflammatory cells to 
contact invading pathogens. Also the fact that mast cells are the only cell-type that 
contain preformed inflammatory mediators makes mast cells as vanguards to control 
bacterial pathogens. Thus, any incapacitation of host defenses at the very early but 
critical stage of infection owing to loss of mast cell function, as demonstrated here, tips 
the balance in favor of Y. pestis and makes them the difference between life and death 
several days later. 
 
 
 
 
 
	   40	  
 
 
Table-1: Total Number of Mast cells 
 Total number of Mast cells 
Days PBS (control) Anti-C kit 
2(ACK2)  
% Decrease % Increase 
D1 267 30 88.8 - 
D3 269 32 88.1 - 
D5 214 216 - 0.93 
D7 149 293 - 96.6 
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Figure 4: Mast cells were sorted and identified as c-Kit+ cells: 3 female young 
B10.T (6R) mice were treated with PBS (A) and Anti-C kit monoclonal antibody (B). 
Anti-c kit treated mice showed lower mast cell count compared to PBS treated mice. 
Data is representative of 2 independent experiments. 
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Figure 5: Survival curve of Anti-C Kit and PBS treated B10.T(6R) mice: 7 
female young B10.T(6R) mice were infected with 1,000 CFUs of Y. pestis KIM5. 
Anti-C kit treated mice succumb to infection. Data is representative of 2 independent 
experiments. 
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Figure 6: Survival of Anti-C Kit and PBS treated B10.T(6R) mice that 
received multiple doses of ACK2: 7 female young B10.T(6R) mice were infected 
with 1,000 CFUs of Y. pestis KIM5. Mice that received multiple dose of Anti-C kit 
antibody succumb to infection earlier than mice that received single dose of anti-c kit 
antibody. Data is representative of 2 independent experiments. 
 
	   44	  
 
 
 
 
 
 
 
 
 
 
 
 
 
 D3
Iso
typ
e
AC
K2 PB
S
0
2
4
6
8
10
12
lo
g 
C
FU
 p
er
 s
pl
ee
n
 D3
lo
g 
C
FU
 p
er
 li
ve
r
Iso
typ
e
AC
K2 PB
S
0
2
4
6
8
10
12
Figure 7: Bacterial burdens in the spleens and livers of infected mice at day 3  
(A & B). Spleens and livers of B10.T(6R) mice challenged with 1,000 CFUs of Y. 
pestis KIM5(n=5/dose/experiment). Data is representative of 2 independent 
experiments; p<0.05 by Bonferroni’s Multiple Comparisons test. 
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Figure 8: Bacterial burdens in the spleens and livers of infected mice at day 6   
(A & B). Spleens and livers of B10.T(6R) mice challenged with 1,000 CFUs of Y. 
pestis KIM5(n=5/dose/experiment). Data is representative of 2 independent 
experiments; p<0.05 by Bonferroni’s Multiple Comparisons test. 
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CHAPTER III 
SUSCEPTIBILITY TO YERSINIA PESTIS IN B10.T (6R) MICE IS DEPENDENT 
ON YOPJ INDUCED VIRULENCE 
 
Introduction 
Three of the 11 species found in the genus Yersinia are pathogenic to humans: 
Yersinia pseudotuberculosis, Yersinia enterocolitica and Yersinia pestis (26). Y. 
pseudotuberculosis and Y. enterocolitica cause gastrointestinal disorders (169) whereas 
Y. pestis is the causative agent of bubonic, pneumonic and septicemic plague (180).  
Plague is transmitted to mammalian hosts via infected flea bites. After transmission to 
mammalian host, the bacteria evade the host innate immune response and colonize the 
proximal lymph nodes (240). The organism will proliferate in the lymph nodes, leading 
to enlarged and inflamed lymph nodes called buboes, a manifestation of bubonic plague. 
From the lymph nodes, the organism spreads systemically to spleen, liver and lungs. 
Colonization of bacteria in lungs can lead to secondary pneumonia and may result in 
person-to-person transmission causing primary pneumonic plague (180). 
Y.pestis has been classified into 4 biovars depending on their ability to reduce nitrate and 
ferment glycerol: Antiqua (positive for both metabolic functions), Mediaevalis (cannot 
reduce nitrate but can ferment glycerol) and Orientalis (can reduce nitrate but cannot 
ferment glycerol) and non-human pathogenic Microtus. Y. pestis CO92 strain (Orientalis) 
is an American isolate from the third plague pandemic (97), while KIM5 strain 
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(Mediavalis) is an isolate from endemic plague foci (176). Both of these strains share 
95% of sequence similarity between the 2 genomes (58), (176). The CO92 genome is ~ 
50 kilobases (kb) larger than the KIM genome due to the presence of an 11 kb and 
several small insertions in CO92 relative to the KIM5 genome. About 27 kb of the 
differences is due to insertion sequence (IS) elements present in CO92 (176). CO92 has 1 
less rRNA operon than KIM. Both of these strains of Y. pestis harbor a 70 kb highly 
conserved plasmid pCD1 (calcium dependence) containing ~ 50 virulence genes 
encoding the type III secretion system (T3SS). The T3SS delivers several effector 
molecules (YpkA, YopH, YopE, YopJ, YopT, YopK and YopM) into the cytosol of host 
cells (169). YopJ, an effector molecule secreted by the T3SS, inhibits the MAPK and the 
nuclear factor-kappa B (NF-κB) pathways. Delivery of YopJ to the host cells prevents the 
formation of anti-apoptotic factors, thereby Yersinia infected macrophages undergo 
apoptosis that requires TLR4-dependent activation of caspases (155, 198, 261, 263). 
YopJ is homologous to CE cysteine proteases (174) and also functions as deubiquitinase 
(175, 224, 267). More recent studies identify YopJ as an acetyl-transferase, activated by 
host-specific factor inositol hexakisphosphate (153). YopJ acetylates Ser and Thr 
residues important for activation of MΚΚs and IΚΚβ pathways (153, 163). YopJ 
mediated acetylation of MAPΚΚs and IΚΚβ directly competes with phosphorylation of 
these residues, thus blocking the signal transduction required for activation of MAPΚ and 
NF-Κβ transcription factors (163). Consequently, transcription of pro-inflammatory 
cytokines and cell survival gene expression is inhibited by YopJ mediated activity. The 
combined effect of YopJ mediated inhibition of cell survival genes and TLR4 dependent 
activation of apoptotic signaling pathways results in Yersinia infected macrophage cell 
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death. Together, lack of the various pro-inflammatory products inhibits the activation and 
recruitment of macrophages and neutrophils to the site of infection and thus Y. pestis is 
able to evade the host inflammatory response (169)  
Y. pestis infected hosts have a lack of early inflammatory responses with immune cell 
depletion at sites of bacterial replication and dampening of pro-inflammatory cytokine 
responses. Although Y. pestis causes deadly infections in hosts, there exists a percentage 
of hosts that are intrinsically resistant to plague (48, 230). Multiple laboratory strains of 
inbred mice are resistant to plague but the mechanisms of resistance and susceptibility are 
poorly understood. Susceptible C57BL/6J mice infected with the KIM5 strain of Y. pestis 
have an LD50 of 20-50 CFUs (48) whereas KIM5 infected 129S2/SV.Hsd have an LD50 
of 2 X 106 CFUs (180). BALB/C strains of mice are susceptible to plague infection, 
however, the BALB/cJ substrain is resistant to plague infection (229). The resistance was 
mapped to a region that coincided with the major histocompatibility complex on 
chromosome 17 (230). Inbred B10.T(6R) mice are significantly more resistant to Y. pestis 
KIM5 than C57BL/6 and other “susceptible” mouse strains, and this resistance decreases 
with age (124)  
Here, the susceptibility of young and middle aged B10.T (6R) mice to Y. pestis CO92 
Δpgm was examined. Interestingly, young B10.T (6R) mice that are resistant to the KIM5 
strain (LD50 of 14,000 CFUs) were susceptible to the CO92 Δpgm strain (LD50 of 9-17 
CFUs).  To our knowledge, this is the first known report to document such a difference in 
the virulence of plague strains. A set of KIM5 isogenic strains expressing various YopJ 
isoforms allowed a demonstration that amino acid differences in YopJ were largely 
responsible for the increased virulence of the pandemic strain, CO92 Δpgm in the 
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B10.T(6R) mice.  Comparison of serum cytokine profiles of sera taken from young 
B10.T(6R) mice infected with either Y. pestis CO92 Δpgm or KIM5 demonstrated that 
pro-inflammatory cytokines (e.g. IL-6, IL-1β) and chemokines (KC, RANTES, and 
MCP1) levels were higher in mice infected with the KIM5 strain compared to the CO92 
Δpgm strain. These results suggest that YopJCO92 is associated with lower cytokine 
production, and that the cytokine changes correlate with the differences seen in virulence 
between the CO92 Δpgm and KIM5 strains of Y. pestis. 
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MATERIALS AND METHODS 
Mice 
6 to 8 weeks of age of female B10.T (6R) mice (original breeding stock a gift from 
Dr. Chella David, Mayo Clinic and College of Medicine, Rochester, MN) were bred and 
maintained in a clean laminar flow containment area within the Center of Biological 
Research (CBR) at University of North Dakota. Young female B10.T (6R) mice were 
used for mortality studies and to determine LD50 for various strains of Y. pestis. The 
University of North Dakota IACUC approved all animal studies  
 
Table 2: Bacterial Strains Utilized 
 
 
 
Bacterial Strains Characteristics Source or 
   Reference 
Y. pestis   
KIM5 
 
    Biovar Mediavalis, pgm-, pCD1, pMT1, pPCP1 
 
(230) 	  
CO92 Δpgm  Biovar Orientalis, pgm-, pCD1, pMT1, pPCP1 
 
J.Bliska 
 
KIM5-YopJCO92 KIM5 pCD1-Ap encodes YopJ L177F E206K, Apr 
 
J.Bliska 
 
KIM5-YopJYPTB   KIM5 pCD1-Ap encodes YopJL177F, Apr 
 
J.Bliska 
 
KIM5-YopJE206K 
 
  KIM5 pCD1-Ap encodes YopJE206K, Apr 
 
J.Bliska 
 
CO92-YopJKIM5 
 
CO92pCD1-Tm encodes YopJF177L K206E, Tmr   
 
This study 
 
   CO92-YopJYPTB 
 
  CO92 pCD1-Ap encodes YopJL177F, Apr 
 
This study 
CO92-YopJE206K 
 
 
     CO92 pCD1-Ap encodes YopJE206K, Apr 
 
    
This study 
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Bacterial Strains, culture conditions and plasmids 
Y. pestis strains as listed in Table 1 lack the pigmentation locus and are exempt from 
select agent guidelines. All strains were stored at -80˚C in 25% glycerol (vol/vol). CO92 
Δpgm, KIM5-YopJCO92, KIM5-YopJYPTB, and KIM5-YopJE206K were a kind gift from 
James B. Bliska.  
 Preparation of YopJ mutants in CO92Δpgm: CO92Δpgm cells were grown on 
Tryptose Blood Agar Base (TBA; BD Difco, Sparks, MD) plates at 26°C for 48 hrs. The 
CO92 Δpgm cells grown at 26°C were plated on TBA plates with 2.5mM concentration 
of CaCl2 at 37°C for several generations to cure the pCD1 plasmid. Growth curve were 
performed as described by Straley et. al. Briefly, bacteria were grown in TMH medium 
(99) at 26°C overnight, subcultured into fresh medium at an A620 0.1(plus 2.5mM CaCl2)  
and grown until OD reaches 0.2 at 620nm. The temperature was shifted to 37°C and 
incubated for 7 h while taking A620 readings at 1 h intervals. 1 ml of sample was 
aliquoted into 1.5 ml tubes, centrifuged at 20000 X g for 5 min at 4°C and pellets 
separated from the supernatant, which contains secreted proteins. The pellet and 
supernatents were precipitated with 10%(w/v) trichloro acetic acid (TCA) followed by 
SDS-PAGE and silver staining to ensure that pCD1 was cured from the CO92 Δpgm 
cells.  This CO92 ΔpCD1 was used to prepare electrocompetent cells. 
      Preparation of CO92 ΔpCD1 electrocompetent cells: CO92 ΔpCD1 cells were 
grown overnight in HIB broth, subcultured into fresh medium to an A620 of 0.1 and grown 
until OD reaches 0.5-0.8.The culture was taken in a 50 ml conical tube, centrifuged at 
3220 X g for 20 min at 4°C. The cell pellet was washed once with cold distilled water at 
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3220 X g for 20 min. The cell pellet was dissolved in 1 ml of cold 10% PEG 8000, 
centrifuged at 20000xg at 3 min at 4°C. The cell pellet was dissolved in 25µl PEG/OD620.      
    The pCD1 plasmid DNA was isolated from D27 YadA:Tmr strain by midiprep 
isolation kit (Qiagen Sciences, Maryland 20874,USA) and used for transformation of 
CO92 Δpgm pCD1-.  
Bacterial Challenge 
Young B10.T (6R) mice were infected intravenously with various strains of Y. pestis 
as listed in Table 1. All strains were grown at 26˚C with shaking overnight in Heart 
Infusion broth (HIB; BD Difco) followed by subculture to 0.1 A620, and incubated at 
26˚C with shaking to an A620 of 1.0. Bacteria were centrifuged at 3,220 X g for 5 min, 
washed twice in sterile phosphate buffered saline (PBS) and resuspended in PBS. Mice 
were monitored twice daily for survival for 21 days. For LD50 studies, challenge 
inoculums were decimally increasing doses of 10¹ to 107 CFU for B10.T(6R) mice. The 
serial dilutions used for infection were plated on TBA (BD Difco, Sparks, MD) plates 
and colonies were counted after 2 days of incubation at 26˚C. 
LD50 calculation 
Mice were monitored daily from inoculation on day 1, until day 21. The experimental 
dose that resulted in death of 50% for the mice infected was determined using log dose 
probit analysis (SPSS version 21.0; IBM Corporation, Somers, NY) 
Measurement of Bacterial Burden 
Livers and spleens were harvested from young infected B10.T (6R) mice and 
incubated in PBS containing 0.1% collagenase D for 1 h at 37°C. The challenge 
inoculum for Y. pestis was the LD50 dose obtained from the mortality study. All organs 
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were homogenized by passage through 70 µM pore-size nylon mesh cell strainers 
(Falcon-Corning Inc, Corning, NY). Homogenates were centrifuged at 3,200 x g at for 5 
min. Pellets were resuspended in PBS containing 0.1% (vol/vol) Triton X-100 to lyse 
eukaryotic cells. Bacterial burden was determined by plating serial dilutions on TBA (BD 
Difco, Sparks, MD) plates. 
Cytokine and Chemokine Analysis 
For cytokine and chemokine analysis, mice were bled retro-orbitally at day 1 and day 
3 post-infection. Blood was pooled, collected in serum separation tubes, centrifuged at 
8,000 X g for 10 min and stored at -80˚C until assayed.  Spleens and livers from infected 
mice were harvested at day 1 and 3 post infection, homogenized by passage through a BD 
falcon 70 µm nylon mesh strainer and the cell pellet contents were washed in 1 ml of 
PBS. Sera, Splenic and liver cytokine and chemokine levels were measured using Bio-
Plex Pro Mouse Cytokine/Chemokine 23-Plex Panel assay (Bio-Rad, Hercules, CA). IL-
1β levels were measured by ELISA (Biorad, Hercules,CA). 
Statistical Analysis 
Data were analyzed using GraphPad Prism (version 5.0d, GraphPad Software Inc, La 
Jolla, CA) to calculate statistical significance. For two group comparisons, a two-tailed 
unpaired t-test was used. For multiple groups, one way analysis of variance (ANOVA) 
with Bonferroni Multiple Comparison test as a post-test, a p value of <0.05 was 
considered significant. 
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RESULTS 
Resistant young B10.T(6R) mice are susceptible to Y.pestis C092 
 Young female B10.T(6R) mice were infected i.v (retro-orbitally) with increasing 
doses of Y. pestis KIM5 or Y. pestis CO92 Δpgm. The LD50 of Y .pestis KIM5 Δpgm in 
young B10.T(6R) mice was 14,000 CFUs (124) whereas the LD50 of Y. pestis CO92 
Δpgm in young B10.T(6R) mice was 17 CFUs (Figure 9A). Interestingly, the young 
B10.T(6R) mice that were resistant to KIM5 (124) were susceptible to the CO92 Δpgm. 
(Figure 9A). The mean times to death were similar for all bacterial strains (4-5 days, data 
not shown). B10.T(6R) mice have decreased resistance to plague with increasing age. To 
determine whether susceptibility to CO92 Δpgm changes with age, groups of middle aged 
B10.T(6R) mice were infected with increasing doses of KIM5 and CO92 Δpgm strains of 
Y.pestis. The LD50 of middle-aged susceptible B10.T(6R) mice infected with Y. pestis 
CO92 Δpgm was 23 CFUs comparable to the LD50 levels observed in middle aged B10.T 
(6R) mice infected with Y. pestis KIM5 where the LD50 was 64 CFUs (Fig 9B) similar to 
a previous report in this plague mouse model where resistance waned with age in female 
B10.T(6R) mice (124). Taken together, these results suggested that the difference in 
virulence between the KIM5 and CO92 Δpgm strains in young B10.T(6R) mice is not due 
to age related factors of the mouse strain but due to differences between the bacterial 
strains. 
YopJ isoforms were responsible for the difference in the outcome of infection in 
young B10.T (6R) mice 
One of the differences between Y. pestis KIM5 and Y. pestis CO92 is a variance in 
YopJ. The YopJ isoform in Y. pestis KIM5 has amino acid differences at two sites, 
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F177L and K206E, compared to YopJ of Y. pestis C092 (264). To understand whether the 
different isoforms of YopJ were responsible for the difference in the outcome of 
infection, young female B10.T(6R) mice were infected with mutants expressing different 
isoforms of YopJ. Mutations that allowed production of the CO92 YopJ in the KIM5 
(KIM5-YopJCO92) strain increased the virulence of Y. pestis KIM5 to approximately the 
same value as the Y. pestis CO92 Δpgm strain (Figure 9A). The LD50 of the KIM5-
YopJCO92 strain was found to be 10 CFUs, significantly reduced from the KIM5 strain 
(14,000 CFUs) (Figure 9A) but similar to the virulence to that of CO92 Δpgm strain 
(Figure 9A). On the contrary, the CO92-YopJKIM5 infected B10.T (6R) mice were found 
to have an LD50 of 243 CFUs (Figure 10A), which lowered the virulence level of the 
CO92 Δpgm strain. The combined data suggested that although CO92 YopJ expression in 
a less virulent strain (KIM5) leads to increased virulence but KIM5 YopJ expression in 
CO92 did not show a reverse effect suggesting that there might be other potential 
virulence factors in the CO92 strain of Y. pestis that might be responsible for the 
increased virulence seen with the CO92 strain in this study. To determine which specific 
amino acid polymorphisms of YopJ were responsible for the increased virulence in CO92 
strain, young female B10.T (6R) mice were infected with Y. pestis strains expressing 
either the F177L (YopJYPTB) or E206K mutations on either the KIM5 or CO92 
background. The LD50 of KIM5-YopJYPTB and KIM5-YopJE206K were found to be 3.6 Χ 
104 and 2.6 CFUs respectively (Figure 10B). Similarly the LD50 of CO92-YopJYPTB and 
CO92-YopJE206K in CO92 background were found to be 2,600 and 62,000 CFUs 
respectively (Figure 10B).  Taken together these data suggest that not a specific amino 
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acid polymorphism but both of the amino acid polymorphisms were responsible for the 
difference in virulence of the two strains. 
Differences in Bacterial Burden in CO92 infected B10.T (6R) mice 
Eventually, Y. pestis infection spreads systemically throughout the visceral organs 
(26). Bacterial burdens were assessed in the spleens and livers of B10.T (6R) mice 
infected with 14000 CFUs of Y. pestis KIM5, 17 CFUs of Y. pestis CO92 Δpgm, 10 
CFUs of KIM5-YopJCO92 and 250 CFUs of CO92-YopJKIM. At 3 d post-infection, KIM5 
infected young B10.T (6R) mice had 9.3 X 107 ± 3.3 X 107(mean ± standard error of 
mean [SEM]) CFU per spleen compared to 1.9 X 107 ± 1.1 X 107(mean ± SEM) CFU per 
spleen of CO92 Δpgm infected B10.T (6R) (Figure 10A). Similarly, at 3 d post-infection, 
the livers of KIM5 infected B10.T (6R) mice had an average bacterial count of 4.9 X 107 
± 6.3 X 106 (mean ± SEM) compared to 1.1 X 107 ± 7.7 X 106 (mean± SEM) that was 
comparatively lower than the bacterial count observed in the spleens of KIM5 or CO92 
Δpgm infected B10.T (6R) mice (Figure 11C and 11A). However, by 6 d post-infection 
both the spleen and livers of CO92 Δpgm infected B10.T (6R) mice contained fewer 
bacteria (9.8 X 104 and 1.86 X105 respectively) than KIM5 infected mice (2.5 X 107 and 
2.83 X 106 respectively) (Figure 11B and 11D). However, the Y. pestis strains expressing 
different isoforms of YopJ (KIM5-YopJCO92 or CO92-YopJKIM) did not show a 
significant change in bacterial burden. These data suggest that CO92 Δpgm infected 
young B10.T (6R) mice were able to successfully induce immune responses to Y. pestis 
and were able to clear the bacteria from visceral organs. 
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Analysis of cytokines and chemokines 
To understand the mechanism of resistance/susceptibility, cytokine and chemokine levels 
were analyzed in the sera of B10.T (6R) mice infected with Y. pestis KIM5, Y. pestis 
CO92 Δpgm, KIM5-YopJCO92 and CO92-YopJKIM. Susceptible B6 mice showed higher 
levels of IL-6 in serum post infection with different doses of KIM5 than resistant 
BALB/cJ mice (229). IL-6 and RANTES levels were higher in CO92 Δpgm, compared to 
KIM5 infected B10.T (6R) mice independent of dose (Figure 12A,B, C). KC and MCP-1 
levels were elevated at only the lower dose, 100 CFUs of CO92 Δpgm compared to 
KIM5-infected mice (Figure 12B &C). Interestingly, at 100 CFUs 1 d post infection, 
there was no difference in serum IL-1β levels between KIM5 and CO92 Δpgm but there 
was a significant difference in the IL-1β levels at 3 d post infection. With the mutant 
strains (KIM5-YopJCO92 and CO92-YopJKIM) either at 100 or 1,000 CFUs there was a 
statistical significant difference in the sera IL-1β levels at 1 d post infection (Figure 13). 
Conversely, at 1,000 CFUs there was a statistical significant difference in sera IL-1β 
levels between the KIM5 and C092 Δpgm strains and the mutant strains (KIM5-YopJCO92 
and CO92-YopJKIM) at 1 d post infection. However, there was no significant difference 
observed in the sera IL-1β levels at 3 d post infection with the mutant strains (KIM5-
YopJCO92 and CO92-YopJKIM). Since Y. pestis infections spread systemically throughout 
the visceral organs (229), cytokine levels were followed to examine if a trend similar to 
that seen in serum occurred in spleens or livers. B10.T(6R) mice were infected with 100 
or 1,000 CFUs of Y. pestis KIM5, Y. pestis CO92 Δpgm, KIM5-YopJCO92 and CO92-
YopJKIM. At 1 d post infection, IL-1β levels were lower in the spleen of mice when 
infected with 100 CFUs of KIM5 strain than CO92 compared to 1000 CFUs infected 
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mice. There was no significant difference observed in the IL-1β levels in the liver at day 
1 post infection when mice were infected with 1000 CFUs of Y.pestis KIM5 or CO92 but 
a statistically significant difference was observed in the livers between the mutant strains 
(Yp-YopJCO92 and Yp-YopJKIM). At 100 or 1000 CFUs IL-1β levels were significantly 
higher in KIM5 infected mice in the spleen or liver at days 3 post infection than CO92 
infected mice suggesting an immunosuppressive role of YopJCO92. This was further 
demonstrated when the mutant strain show a similar trend in suppressing the IL-1β levels 
in the spleen or liver when Yp-YopJCO92 expression in the KIM5 strain lowered IL-1β 
production compared to the expression of Yp-YopJKIM in CO92 when B10.T (6R) mice 
were infected with 1000 CFUs of bacteria.  
IL-1 receptor antagonist (IL-1Ra) levels in Y. pestis infected B10.T (6R) mice 
IL-1 receptor antagonist proteins are expresses by macrophages and neutrophils to 
dampen the pro-inflammatory response. We sought to determine whether production of 
IL-1Ra by YopJCO92 is able to dampen the pro-inflammatory immune response (Figure 
14). As expected at day 3 there was a higher amount of IL-1Ra in the sera of CO92 
infected B10.T (6R) mice than KIM5 infected B10.T (6R) mice irrespective of the dose 
used (100 or 1000 CFUs). At day 3 both the CO92 infected spleen and liver showed 
higher amount of IL-1Ra than KIM5 infected B10.T (6R) mice suggesting that YopJ of 
CO92 might be responsible for suppressing the immune response (lower IL-1β 
production). 
Discussion 
Y.pestis has developed innumerable ways to manipulate and evade host immune 
response. Y.pestis like other Gram-negative bacteria has lipopolysaccharide (LPS) in its 
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outer membrane. LPS is a ligand for Toll-like-Receptor (TLR4). Based on temperature, 
Y.pestis synthesizes two forms of LPS: tetra and hexa-acylated LPS (157). At 26ºC, 
bacteria grown in flea gut produce a hexa-acylated LPS, which elicits TLR4-mediated 
immune signaling to induce pro-inflammatory cytokines such as TNF-α, IL-1β, IL-6 and 
IL-8 (157). After infection of the mammalian host, the temperature shift from 26ºC to 
37ºC lets Y.pestis synthesize tetra-acylated form of LPS that is inhibitory for TLR4 
mediated immune signaling resulting in resistance to complement-mediated lysis and 
repression of pro-inflammatory cytokines (64, 157). During early stages of infection, the 
bacteria are phagocytosed by macrophages and neutrophils at the site of infection. Flow 
cytometry data and histological evidence suggests that Y. pestis are killed by neutrophils 
and that neutrophils can control Y.pestis growth up to two days post infection (140). 
However, in the phagolysosome of the macrophages Y.pestis can survive and proliferate 
(221). This intracellular growth is important for Y.pestis pathogenesis to express various 
virulence determinants like F1 antigen and V antigen and various effector molecules 
secreted by the type III secretion system (T3SS) (188).  
YopJ one of the effector molecules of T3SS, is an acetyl transferase and inhibits NF-
Κβ and MAPK signaling pathways. Additionally, YopJKIM has higher affinity for IΚΚβ, 
triggers apoptosis, caspase-1 activation and IL-1β secretion than other isoforms of YopJ 
(265). The amino acid substitution present in YopJ in Y. pestis KIM5 at two sites, F177L 
and E206K, compared to the YopJ present in Y. pestis CO92 accounts for the various 
phenotypes seen in bone marrow derived macrophages (265). How these polymorphsims 
in YopJ affects virulence of Y.pestis and or host response is not known.  
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Previous reports demonstrated that young B10.T(6R) female mice are highly resistant 
to infection with Y.pestis KIM5 and this resistance is abolished with age (124). Studies 
show that B10.T(6R) mice are resistant to Trichuris muris infection (69). H-2q haplotype 
of B10.T(6R) mice is associated with resistance to Trichuris muris infection(69). 
B10.T(6R) mice is a substrain of C57BL/10SnSg mice that differ at H-2 locus . Other 
inbred mice that are resistant to Y.pestis infection are 129 substrains or BALB/cJ mouse 
strain, which is also linked to H-2b or H-2bc and H-2d respectively (230). However, 
whether this resistance to Y.pestis is related to H-2q haplotype is not known. 
Using this model of resistant B10.T (6R) mice, we sought to determine the LD50   of 
B10.T(6R) mice when infected with Y.pestis CO92 strain. As shown in this study the 
LD50 observed in young female B10.T (6R) mice was 17 CFUs when infected with CO92 
strain of Y.pestis while the LD50 observed with KIM5 strain of Y.pestis was 14000 CFUs. 
Interestingly, the young B10.T(6R) mice that were resistant to KIM5 strain of Y. pestis 
were susceptible to the CO92 strain of Y. pestis. A similar experiment was done with 
female middle-aged B10.T(6R) mice infected with KIM5 or CO92 strain of Y. pestis. The 
LD50 observed for CO92 was 23 CFUs comparable to 64 CFUs when female middle-aged 
B10.T(6R) mice were infected with Y. pestis KIM5. These results suggested that the 
difference in virulence observed between the two strains is not due to age related factors 
but due to a difference in the bacterial strain. We hypothesize that in our model, different 
isoforms of YopJ present in KIM5 and CO92 strain of Y.pestis is responsible for the 
difference in the outcome of infection. As shown in Figure 2, production of YopJCO92 in 
KIM5 strain increased virulence level of KIM5 to same value as Y. pestis CO92 
suggesting that YopJ is responsible for the difference in virulence. However, when 
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YopJKIM5 was expressed in CO92 strain the LD50 levels did not increase to same value as 
KIM5 strain but lowered the virulence level of CO92 strain indicating that there are other 
possible virulence factors in CO92 that is responsible for the increased virulence seen in 
Y. pestis CO92 strain.   
The kinetics of our infection model suggests that bacterial clearance begins at spleen 
followed by liver at three days post infection. There was higher bacterial burden in the 
spleens and or liver of KIM5 infected B10.T (6R) mice compared to CO92 infected mice. 
The higher bacterial burden observed in KIM5 infected mice might be due to the higher 
amount of bacteria (LD50 dose of 14000 CFUs) inoculated into the mice compared to the 
LD50 doses (10,20, 250 CFUs) used for the other strains (CO92, Yp-YopJCO92 and Yp-
YopJKIM). 
The immunological response observed in young B10.T(6R) mice when infected with 
KIM5 or CO92 strain of Y.pestis were compared by analyzing various cytokine and 
chemokine level. IL-6, and RANTES levels were higher in young female B10.T(6R) 
mice when infected with Y. pestis CO92 strain compared to infection by KIM5 strain 
irrespective of the CFUs doses used. On the contrary, IL-1β levels were higher in the sera 
of B10.T (6R) mice infected either with 100 or 1000 CFUs of Y. pestis KIM5 compared 
to Y. pestis CO92 both at days 1 and 3 post infection. IL-6 down regulate the 
proinflammatory response (112, 202) , strongly supports the importance of the cytokine 
in both neutrophil recruitment and regulation of the immune response. KIM5 infected 
B10.T (6R) mice exhibited lower levels of IL-6, and this in return may influence levels of 
proinflammatory mediators IL-1β. In humans, there is a positive correlation between 
serum IL-6 levels and disease outcome in septic patients (36, 41, 56). In experimental 
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sepsis models, blockage of IL-6 increases survival in a polymicrobial sepsis model (218). 
Since the host is thought to succumb to sepsis during the late stages of Y. pestis infection 
(27) and IL-6 is elevated in both clinical and experimental models, the elevated levels of 
IL-6 in CO92 infected B10.T(6R) mice in our model may be a result of YopJ-induced 
sepsis. The lower IL-6 levels observed in KIM5 infected B10.T(6R) mice may be more 
reflective of a controlled inflammatory response, with the anti-inflammatory role of IL-6 
downregulating other inflammatory mediators like IL-1β. 
Splenic and liver IL-1β levels were also significantly elevated in KIM5 infected 
B10.T(6R) mice than CO92 infected B10.T(6R) mice. This is in accordance to the 
findings observed in in vitro studies where YopJKIM triggers caspase-1 activation and 
which in turn elevates the IL-1β levels whereas YopJCO92 suppresses IL-1β activation in 
bone marrow derived macrophages (264). Mutants expressing different isoforms of YopJ 
showed that YopJCO92 when expressed in KIM5 strain suppresses IL-1β levels whereas 
expression of YopJKIM in CO92 strain elevated IL-1β levels. These findings suggest that 
YopJ of Y. pestis CO92 is able to suppress the production of these cytokines in 
B10.T(6R) mice. Although the IL-1β levels were higher in the later stages of infection yet 
there was no significant difference in the IL-1β levels at day 6 post infection (data not 
shown) between the KIM5 or CO92 strain. This observation can be explained that at later 
stages of Y. pestis infection, normally, it is too late for the host to clear the bacteria and 
the host succumbs rapidly to sepsis due to the systemic burden of the growing bacteria 
and overwhelming cytokine production by the host (56). 
These results suggest a model whereby the recognized YopJ allele of KIM5 strain has 
higher apoptotic or caspase-1 activating potential (264) which in turn increases the IL-1β 
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levels. The phenotype observed by YopJKIM might be due to F177L mutation. On the 
other hand, YopJ CO92 allele evolved from Y. pseudotuberculosis (132) has lower 
cytotoxic and caspase-1 activating potential and hence produce lower IL-1β levels. This 
observation might be due to the E206K codon substitution present in the YopJ of CO92 
strain.  
Taken together we demonstrated that the YopJ of Y. pestis KIM5 is an important 
virulence factor and contributes to the susceptibility observed in our previous plague 
resistant B10.T (6R) mice model. Additionally, our data indicated that the YopJ of Y. 
pestis CO92 had the ability to suppress cytokine production in vivo and thus modulating 
host immune responses. Our future studies are targeted at better understanding the role of 
Y.pestis induced sepsis using this model of B10.T (6R) mice.  
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Figures  
 
Figure 9: Difference in LD50 between the KIM5 and CO92 Δpgm strain of 
Y.pestis.(A) Young (6-8wks) female B10.T(6R) mice were infected i.v via the retro-
orbital sinus with increasing doses of Y.pestis KIM5 & CO92 strains . After 21 days of 
monitoring LD50 was calculated using log-dose probit analysis (at a 95% confidence 
level). (B) LD50 of middle aged female B10.T(6R) mice. Data are representative of 2 
independent experiments(n=7/dose group/experiment) 
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Figure. 10: Different isoforms of YopJ are responsible for the difference in the 
outcome of infected mice. A) Young (6-8wks) female B10.T(6R) mice were infected i.v 
via the retro-orbital sinus with increasing doses of Y.pestis KIM5-YopJCO92 & CO92-
YopJKIM5. After 21 days of monitoring LD50 was calculated using log-dose probit analysis  
(at a 95% confidence level). B) Young female B10.T(6R) mice were infected i.v via the 
retro-orbital sinus with increasing doses of Y.pestis strains expressing either F177L 
(YPTB) or E206K mutations on either KIM5 or CO92 background (KIM5-YopJYPTB, 
KIM5-YopJE206K, CO92-YopJYPTB and CO92-YopJE206K). Data are representative of 2 
independent experiments(n=7/dose group/experiment) 
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Figure 11: Bacterial burdens in the spleens and livers of infected mice B10.T(6R) 
mice were infected with various strains of Y.pestis( KIM5, CO92 Δpgm, KIM5-YopJCO92 
and CO92-YopJKIM) with LD50 dose :14000 CFUs, 17 CFUs, 250 CFUs and 10 CFUs 
respectively. Spleen (A&B) and Liver (C&D) were collected at d3 and d6 post infection 
(n=3/dose/experiment). Data is representative of 2 independent experiments; p<0.05 by 
Bonferroni’s Multiple Comparisons test. 
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Figure 12: IL-6 and chemokine levels in KIM5 and CO92 Δpgm infected 
B10.T(6R) mice. B10.T (6R) female mice were infected with 100 CFUs or 1000 
CFUs of KIM5 and CO92 Δpgm and sera was collected at day 3 post infection to 
measure IL-6 (A) and chemokine (B&C) respectively. Data is representative of 3 
independent experiments; p<0.05 “*” p<0.001 “***” by Student’s t test. 
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Figure 13: IL-1β levels in infected B10.T (6R) mice. B10.T(6R) mice were infected 
with various strains of Y.pestis (KIM5, CO92 Δpgm, Yp-YopJCO92 and Yp-YopJKIM) at 
100 CFUs (D-I) and 1000 CFUs (K-P). IL-1β levels were measured in the sera, spleens 
and liver at days 1 and 3 post infection by ELISA. p<0.05 =* p<0.001=*** or p<0.01** 
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Figure 14: IL-1Ra levels in infected B10.T (6R) mice. B10.T(6R) mice were 
infected with various strains of Y. pestis (KIM5, CO92 Δpgm, Yp-YopJCO92 and Yp-
YopJKIM) at 100 CFUs (A-F)) and 1000 CFUs (G-L). IL-1Ra levels were measured in the 
sera, spleens and liver at days 1 and 3 post infection by ELISA. p<0.05 =* p<0.001=*** 
or p<0.01** 
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CHAPTER IV 
ROLE OF IRON IN RESPONSE TO YERSINIA PESTIS INFECTION  
          Introduction 
Yersinia pestis, a Gram-negative bacterium belonging to the Enterobacteriaceae family is 
the causative agent of plague. Plague is transmitted either by bite of an infected flea or 
can directly be transmitted by aerosol causing bubonic and pneumonic plague 
respectively (180). Humans inoculated with a live attenuated Y. pestis strain or Y. pestis 
EV76 as a live attenuated vaccines provides protection against bubonic and pneumonic 
plague (91, 150) . 
Classified as a category A select agent, Y. pestis requires special precautions because of 
the risk of transmission of plague. One of the major obstacles to study pathogenesis of Y. 
pestis is that many laboratories do not have access to biosafety level 3 (BSL-3). As a 
result, laboratories cannot work with the fully virulent strain of Y. pestis. Hence use of 
attenuated strain of Y. pestis that are exempt from CDC select agent list is required. Such 
strains lack either pCD1 or the pigmentation (pgm) locus (179). Upon contact with host 
cells, the pCD1 plasmid encodes a type III secretion system that secretes effector 
molecules to the cytosol of host cells that modulate the host immune response (228, 234). 
One of the virulence components in the 102 kb pgm locus is the yersiniabactin (Ybt 
siderophore) dependent iron transport system that is important for pathogenesis of Y. 
pestis from peripheral sites (191). Mutants that lack pgm or pCD1 can be used to study in 
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BSL-2 laboratories. However, the disease caused by the attenuated strains does not 
recapitulate the disease progression observed with the fully virulent strains of Y. pestis 
(158). Compared to the wild type strains, attenuated strains are unable to cause disease 
from natural routes of infection.  
Efficient iron acquisition systems are essential for Y. pestis to spread systemically in the 
host. The Ybt system includes a series of enzymes responsible for the siderophore’s 
biosynthesis. The iron/yersiniabactin complex is attached to the outer membrane (OM) 
receptor Psn and transferred into the periplasm via the TonB-dependent energy pathway. 
Transfer of iron into the cytoplasm is initiated when the iron/siderophore complex 
attaches itself to the periplasmic surface of the inner membrane-localized ATP-binding 
cassette (ABC) transporter YbtP/YbtQ. The YbtP/YbtO contains two permease and two 
ATP-binding domains. For bacterial infection to occur by subcutaneous routes, a 
functional Ybt transporter is required to acquire iron in early stages of the bubonic plague 
in mice (18, 74). Another study from a bubonic plague model suggests that the 
manganese- and iron-specific ABC transporter Yfe is also important for full Y. pestis 
virulence (17). Other ABC transporters for iron (Yfu and Yiu) and hemin (Hmu) are not 
required for virulence in the mouse model (93, 118, 225). The transporters Yfe and Feo 
are redundant in function in ferrous iron acquisition under microaerophilic growth 
conditions (182).  
Various studies demonstrate the role of iron in host response against pathogens. Iron 
overload makes the host susceptible to pathogens as seen in infection studies with 
Listeria monocytogenes (241), Candida albicans (149) and in polymicrobial lung 
infections (172). Iron stimulates bacterial growth (178) and inhibits the antimicrobial 
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activity of leukocytes. (92,114). Iron overload impairs both T and phagocytic cell 
functions. Th1 and Th2 cell proliferation (226), expression of NO synthase (iNOS) in 
murine macrophage cell line, and impairment of phagocytic and neutrophil cell function 
(239) are also affected by iron overload. A genetic condition that is associated with iron 
overload is hereditary hemochromatosis. Recently, non-pigmented Y. pestis strain 
UC91309 was isolated from a researcher with fatal, septicemic plague. The patient had 
higher level of iron deposits in the liver and increased levels of serum ferritin, iron, and 
iron saturation. Sequencing of the patient’s genome linked his death with the HFE C282Y 
mutation associated with hereditary hemochromatosis (44, 81, 190).   
Y. pestis KIM5 lacks the pgm locus and KIM5 is attenuated when given subcutaneously 
to C57BL/6J mice. Y. pestis KIM5 , when injected intranasally into mice, there were less 
bacterial growth in the lungs. Mice did not develop pneumonia as they would have 
developed with the fully virulent strain of Y. pestis (129). However, strain KIM5 was able 
to grow in the spleen and liver of intranasally infected mice suggesting that the pgm locus 
is important for iron uptake in the lungs. Alternative studies show that with iron sulfate 
administration to mice followed by infection with KIM5 Δpgm strain subcutaneously, 
mice died; these results suggest that ferrous sulfate could bypass the need for 
yersiniabactin, rendering KIM5 Δpgm fully virulent. Mice developed histological lesions 
in the livers and spleens resembling the lesions observed in mice when infected by the 
fully virulent strains of Y. pestis (33, 129). However, use of the same method to induce 
pneumonic plague by administering ferrous chloride followed by infection with KIM 
D27 did not show the same results as the subcutaneous model of plague (100). Moreover, 
a dose higher than 0.5 mg per mouse of ferrous chloride was shown to be toxic.  
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The toxicity of inorganic iron and the need to treat patients with iron resulted in the 
development of less toxic colloids comprising of carbohydrates conjugated to ferric 
hydroxides (57). Administration of iron dextran to mice following infection was found to 
be nontoxic. Previously we have shown that the LD50 of young B10.T (6R) mice for Y. 
pestis CO92 Δpgm strain was 17 CFUs whereas the LD50 of young B10.T(6R) mice for 
Y. pestis KIM5 was 14,000 CFUs when infected retro-orbitally (i.v.). But when young 
B10.T (6R) mice were infected with 17 CFUs of Y. pestis CO92 Δ pgm strain and 14000 
CFUs of KIM5 subcutaneously, all mice survived. Here, we develop a bubonic plague 
model in B10.T (6R) resistant mice using iron dextran following infection that will mimic 
the natural infection route caused by the fully virulent Y. pestis and also to understand the 
role of iron in the host immune system. 
We demonstrate that resistant B10.T (6R) mice when treated with iron dextran before and 
after infection with various strains of Y. pestis subcutaneously mimics the infection route 
caused by the fully virulent Y. pestis. To our surprise, supplementing the B10.T (6R) 
mice with iron, followed by infection with KIM5 or CO92 s.c, lowered the mean day of 
death in KIM5 and CO92 infected young female resistant B10.T(6R) mice. The observed 
LD50 of B10.T(6R) mice when infected with CO92 Δpgm strain and KIM5 s.c with iron 
is found to be 20 CFUs and <1000 CFUs respectively whereas the LD50 of B10.T(6R) 
mice when infected with CO92 Δpgm and KIM5 s.c without iron is 6*10^5 CFUs and 
>10^5 CFUs respectively. Also, supplementing the resistant B10.T (6R) mice with iron 
dextran following Y. pestis infection, suppresses the host immune response as shown by 
the lower activity of neutrophils. Iron alone suppressed the ROS levels of neutrophils. 
KIM5 or CO92 Δpgm infected neutrophils treated with iron had lower ROS levels than 
	   74	  
KIM5 or CO92 Δpgm infected neutrophils without treatment with iron. This suggests that 
iron might be a contributing factor in suppressing the host immune system in response to 
Y. pestis. Taken together, this mouse model provides an intriguing system to study host 
immune response to Y. pestis. 
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MATERIALS AND METHODS 
Mice 
6 to 8 weeks of age of female B10.T(6R) mice (original breeding stock a gift from Dr. 
Chella David, Mayo Clinic and College of Medicine, Rochester, MN) were bred and 
maintained in a clean laminar flow containment area within the Center of Biological 
Research (CBR) at University of North Dakota. Young female B10.T(6R) mice were 
used for mortality studies and to determine LD50 for various strains of Y. pestis. The 
University of North Dakota IACUC approved all animal studies. 
Iron Treatment 
Prior to infection with Y. pestis, all female young B10.T (6R) mice were injected 
intraperitoneally (i.p) with 4 mg of iron dextran 1 day before and every alternate day post 
infection. 
Bacterial Challenge 
Young B10.T(6R) mice were infected with various strains of Y. pestis,  KIM5 or CO92 
Δpgm either subcutaneously or intravenously. All strains were grown at 26˚C with 
shaking overnight in Heart Infusion broth (HIB; BD Difco) followed by subculture to 0.1 
A620, and incubated at 26˚C with shaking to an A620 of 1.0. Bacteria were centrifuged at 
3,220 x g for 5 min, washed twice in sterile phosphate buffered saline (PBS) and 
resuspended in PBS. Mice were monitored twice daily for survival for 21 days. The 
challenge inoculums were decimally increasing doses of 103 to 105 CFU for KIM5 strains 
and decimally increasing doses of 101 to 103 CFUs for CO92 Δpgm strains. The serial 
dilutions used for infection were plated on TBA (BD Difco, Sparks, MD) plates and 
colonies were counted after 2 d of incubation at 26˚C. 
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Isolation Of Neutrophils 
Neutrophils were collected from young B10.T(6R) mice as previously described (141). 
Briefly, neutrophils isolated from mouse peritoneal cavity were further separated and 
purified by MACS neutrophils isolation kit (Macs Miltenyi Biotec, San Dieogo, CA). For 
flow cytometry, cells were centrifuged for 5 min at 200 X g at room temperature. Cells 
were resuspended in PBS containing 0.1% BSA to a density of 1 X 106 cells/ml. The cells 
were fluorescently stained for 1h at 4°C in the dark with the following antibodies: FITC-
conjugated anti-F4/80, PE-conjugated anti Ly-6G (eBioscience). The excess antibody 
was washed by adding 1 ml of PBS containing 0.1% BSA and centrifuged for 5 min at 
200 X g at 4°C. The cell pellet was resuspended in 500 µl of PBS containing 0.1% BSA 
buffer. Neutrophils were sorted and identified as Ly-6G+ cells whereas macrophages 
were identified as F4/80+ cells. Flow cytometry analysis was performed on an LSR II 
flow cytometer (BD).  The histogram overlays were constructed using FlowJo (V.7.6.4).  
Measurement of Reactive Oxygen Species (ROS) 
The neutrophils isolated were used to determine ROS levels. 2 X 105 cells /well were 
plated in a 96 well plate. Cells were washed three times with 1X Hank’s Balanced Salt 
solution (HBSS) (Gibco Life technologies, Grand Island, NY) treated with 1 X 2’, 7’- 
Dichlorodihydrofluorescin diacetate (DCFH-DA)/media solution and incubated for 30-60 
minutes at 37°C. (Briefly, the DCFH-DA diffuses into cells and is deacetylated by 
cellular esterase to non fluorescent 2’, 7’- Dichlorodihydrofluorescin (DCFH), which is 
rapidly oxidized to highly fluorescent 2’,7’ Dichlorodihydrofluorescein (DCF) by ROS). 
The solution was removed and washed multiple times with 1X HBSS. The DCFH-DA 
loaded cells were treated with desired oxidant PMA (positive control), PBS (negative 
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control), iron, and bacteria (KIM5, CO92 Δpgm) with and without iron in 100µl of 
medium. ROS levels were immediately analyzed. A kinetic analysis in increments of 10 
minutes up to 2 hours was done using a fluorometric plate reader (Bio Tek) at 480nm/530 
nm.  
Cytokine Analysis 
Iron dextran treated B10.T (6R) mice were infected with various strains of Y. pestis at 
LD50 dose (KIM5=14,000 CFU; CO92-YopJKIM5= 10 CFUs; CO92= 17 CFUs; KIM5-
YopJCO92 = 243 CFUs) Sera was collected at 1 d, 3 d, 5 d, 7 d post infection to measure 
IL-1β levels by ELISA. 
LD50 calculation 
Mice were monitored daily from inoculation on day 1, until day 21. The experimental 
dose that resulted in death of 50% for the mice infected was determined using log dose 
probit analysis (SPSS version 21.0; IBM Corporation, Somers, NY) 
Statistical analysis 
Data in the Figures are expressed as the mean ± SEM. For mortality studies, statistical 
comparisons were carried out using Log-rank (Mantel-Cox) test in GraphPad Prism 
(version 5.0d, GraphPad Software Inc, La Jolla, CA). For two group comparisons, a two-
tailed unpaired t-test was used. For multiple groups, one way analysis of variance 
(ANOVA) with Bonferroni Multiple Comparison test as a post-test, a p value of <0.05 
was considered significant. 
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Results 
Rapid increase in infection when mice were treated with iron dextran 
To determine whether the outcome of infection would be similar in mice infected via 
peripheral routes that mimic the natural route of plague infection, B10.T (6R) mice were 
infected with Y. pestis KIM5 or CO92 Δpgm. All bacterial strains are conditionally 
virulent strains of Y. pestis due to the lack of the pigmentation locus (Δpgm) (179). A 
major component contributing to virulence in the pgm locus is the yersiniabactin-
dependent iron transport system (181) that is important for infection via peripheral routes. 
These conditionally virulent strains of Y. pestis are not capable of inducing disease via 
peripheral routes of infection as observed with pgm+ strains of Y. pestis (237). However, 
they are fully virulent when administered intravenously. When infected intravenously 
(i.v.) the LD50 for Y. pestis CO92 Δpgm and Y. pestis KIM5, in young female B10.T(6R) 
mice was 17 CFUs and 14,000 CFUs, respectively. We show here that when young 
female B10.T (6R) mice were infected subcutaneously (s.c.) with Y. pestis KIM5 or 
CO92 Δpgm all mice survived.  The LD50 of young female B10.T (6R) mice infected s.c. 
with CO92 Δpgm or KIM5 was shown to be 6 X 105 CFUs and >105 CFUs, respectively. 
However, supplementing young female B10.T (6R) mice with iron, prior to s.c. infection, 
resulted in LD50’s of 20 CFUs for the CO92 Δpgm strain and <1000 for the KIM5 strain, 
and the mean day of death was lowered (3-4 days) with both KIM5 and CO92 Δpgm 
strains (Fig 15).  We then examined if iron supplementation would alter the resistance 
observed to KIM5 infection in young female B10.T (6R) mice when infected i.v. The 
LD50 of KIM5 in young female B10.T (6R) mice when infected i.v following iron 
supplementation was 140 CFUs (Fig 16), 2 fold lower than the LD50 observed without the 
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addition of iron, suggesting that iron manipulation might alter the immune response of 
the resistant B10.T(6R) mice making the resistant mice more prone to infection. 
Analysis of cytokines 
IL-1β levels were analyzed in the sera of B10.T (6R) mice infected with Y. pestis KIM5 
or CO92 Δpgm (Figure 17). At day 1, there was a statistically significant difference in the 
sera IL-1β levels between KIM5 and CO92 Δpgm infected B10.T(6R) mice. Iron dextran 
treated CO92 Δpgm infected B10.T(6R) mice showed a lower IL-1β level production 
than iron dextran treated KIM5 infected B10.T(6R) mice. Conversely, at day 3, 5 and 7 
there was no statistically significant difference between iron treated KIM5 or CO92 
Δpgm infected B10.T(6R) mice, however there was a lower production of IL-1β levels 
when B10.T(6R) mice were infected with CO92 Δpgm suggesting an immunosupressive 
role of  iron. 
Suppression of neutrophil ROS levels by iron 
Various reports indicate the role of iron in suppression of the immune response (246). 
Iron has been shown to regulate nitric oxide synthase activity in neutrophils. Here we 
show that neutrophils isolated (Figure 18) and treated with iron alone is suppressing the 
ROS levels. Phorbol Myristate Acetate or PMA activates neutrophils but addition of iron 
to these activated neutrophils show a lower production of ROS levels. KIM5 or CO92 
Δpgm infected neutrophils treated with iron had lower production of reactive oxygen 
species (ROS) levels than KIM5 or CO92 Δpgm infected neutrophils without iron 
treatment with iron (Figure 19). This suggests that iron might be a contributing factor in 
suppressing the host immune system in response to Y. pestis.  
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Discussion 
 A major problem to identify and characterize new immunogens is the need to undertake 
experiments with wild type Y. pestis. However, to work with the fully virulent Y. pestis a 
BSL-3 facility is required. Use of attenuated strains is more common due to the 
availability of BSL-2 facilities in most laboratories. Use of KIM5 or CO92 ∆pgm strains 
of Y. pestis that lack the pigmentation (pgm) locus is more usual. The pgm locus encodes 
the biosynthetic proteins for siderophore yersiniabactin that scavenges iron from the 
mammalian system and is important for progression of disease via peripheral routes of 
infection (180). Mice infected with Y. pestis pgm strains via peripheral routes 
(intradermal or subcutaneous) are unable to cause disease.  Hence disease progression 
induced by Y. pestis pgm strains does not recapitulate the disease that observed with the 
fully virulent strain of Y. pestis via natural routes of infection (75), (158), (129). As 
shown by Galvan et.al, infection of mice was unsuccessful after administering KIM5 by 
the intranasal route; the bacteria proliferated poorly in the lungs and showed no 
significant histopathology (87). Numerous studies indicated that iron injections given to 
mice could suppress pgm attenuation in Y. pestis (33). Treatment of mice with ferric 
chloride and iron sulfate following intranasal infection with KIM5 was able to induce 
pneumonic plague. Proliferation of bacteria in the lungs and survival curves showed that 
the spread of infection was similar to that observed with wild type virulent Y. pestis 
(5),(125),(129). Interestingly, we have shown a similar trend where treating the B10.T 
(6R) with iron dextran following subcutaneous infection with the KIM5 or CO92 Δpgm 
strain showed a lower survival rate than non iron-dextran treated mice (Figure 15).  
Subcutaneous infection with CO92 Δpgm or KIM5 was shown to have an LD50 of 6 X 
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105 CFUs and >105 CFUs, respectively in B10.T (6R) mice. Prior to subcutaneous 
infection, supplementing young female B10.T (6R) mice with iron, resulted in LD50’s of 
20 CFUs for the CO92 Δpgm strain and <1000 for the KIM5 strain, and the mean day of 
death was lowered (3-4 days) with both KIM5 and CO92 Δpgm strains. We then studied 
if iron supplementation would alter the resistance observed to KIM5 infection in young 
female B10.T (6R) mice when infected intravenously (i.v). Following iron 
supplementation, intravenous infection of young female B10.T (6R) mice with Y. pestis 
KIM5 lowered the LD50 to 140 CFUs (Figure 16), 2 fold lower than the LD50 observed 
without the addition of iron, suggesting that iron manipulation might alter the immune 
response of the resistant B10.T (6R) mice making the resistant mice more prone to 
infection. A potential caveat for iron-treated mouse models is that iron can impact the 
host’s innate immune responses, where virulent bacteria can multiply better in iron-rich 
phagocytes (88, 154, 242). Also, iron administration renders mice more susceptible to 
human pathogens, a method that has been used to develop a variety of infectious-disease 
models (217, 243, 258). 
    Bacterial pathogens prevent the early recruitment of neutrophils to infected organs 
during infection. This provides an obvious advantage because neutrophils with their 
various antimicrobial capabilities would otherwise phagocytize the pathogen and undergo 
apoptosis. Y. pestis manipulates a variety of mechanisms in the host immune response to 
evade and survive the early stages of infection. Evidence based on studies in various 
animal models of pneumonic or bubonic plague indicates that following airway or 
intradermal infection with Y. pestis, there is a delay in the early stimulation of a pro-
inflammatory immune response as well as the recruitment of neutrophils to the site of 
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infection (5, 30, 125) . 
     The TTSS is one of the factors that contribute to virulence in pathogenic Yersinia 
strains. The effector proteins secreted by the TTSS are used by the pathogen to subvert 
early innate immune responses (52, 234). In addition to the pCD1 plasmid encoded 
virulence factors, the chromosomal 102-kb pgm locus is also important for virulence of Y. 
pestis in mammals and transmission of Y. pestis via blocked fleas. Efficient iron 
acquisition systems are required for Y. pestis to spread and grow in mammalian hosts. 
The Pgm+ phenotype of Y. pestis shows various traits comprising of adsorption of large 
amounts of hemin at 26°C, mediated by expression of several iron regulated proteins, 
ability to grow in iron chelated media ta 37°C, important for virulence in mice infected 
by peripheral routes of injection and sensitivity to bacteriocin pesticin. Non- pigmented 
(Pgm-) Y. pestis lack all the above-mentioned traits. As iron is important for growth of Y. 
pestis in mammals, iron overload is equally harmful for the host. Various studies shows 
that iron overload in certain tissues was proposed to play a role in pathogenesis of HIV 
and its opportunistic infection (23). Other studies show that iron overload may predispose 
a patient to Candida albicans infections (149). The hereditary condition 
‘hemochromatosis’, which is associated with excessive build-up of iron makes people 
more vulnerable to the plague (190). In neutropenia, availability of decreased lactoferrin 
is associated with impaired iron-withholding defense system, hence increased risk of 
infection. Transferrin (39, 68, 72, 196), a serum protein that binds iron with high affinity, 
restricts free iron availability to levels insufficient for microbial growth (241). Various 
studies indicate a link between iron metabolism and cell-mediated immunity (245). Both 
iron deficiency and iron overload can exert subtle effects on the immune status by 
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altering the T and B cell proliferation (226, 245). Additionally, iron plays an important 
role in the antimicrobial activities of neutrophils and macrophages (231, 232), regulating 
expression of iNOS gene (246).  
The results of the present study show that treatment of neutrophils with iron dextran (10 
ng/ml) in vitro suppresses the ROS levels. When neutrophils were infected with KIM5 or 
CO92 Δpgm there was a higher production of ROS level as compared to neutrophils that 
were treated with iron dextran following infection with either Y. pestis KIM5 or CO92 
Δpgm. This result suggests that suppression of ROS levels might be attributed to iron 
overload.  Since neutrophils are the first cell type to respond to the site of infection and 
also aids to clear the pathogen, this function of neutrophils might be responsible why we 
are seeing a lower mean day death (3-4 days) and lower LD50 when Y. pestis infected 
mice are supplemented with iron. Supplementing the mice with iron suppresses the 
immune response by lowering the recruitment of neutrophils as well ROS production by 
neutrophils. As a result neutrophils are unable to clear the bacteria that resulted in lower 
LD50. 
 In conclusion, the present study shows that disturbances of iron metabolism may 
profoundly affect ROS production by neutrophils, thus altering the course and outcome 
of infection. An alternative experiment with iron chelation might be responsible for 
canceling the iron induced immune suppression thus offering the potential for new 
strategies of immune intervention in plague.  
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Figure 15: Survival curve of B10.T (6R) mice infected with KIM5 and CO92 Δpgm 
strains subcutaneously (A&B). Each group of mice underwent iron supplementation by 
receiving iron dextran (4mg/ml) i.p before infection and every alternate days post 
infection. Mice were challenged with indicated doses of KIM5 and CO92 Δpgm strains.  
and monitored twice daily for 21 days. Data is representative of two independent 
experiments (n=7/dose group/experiment).  
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Figure 16: Survival curve of B10.T(6R) mice infected with KIM5 strain 
intravenously. Each group of mice underwent iron supplementation by receiving iron 
dextran (4mg/ml) i.p before infection and every alternate days post infection. Mice were 
challenged with indicated doses of KIM5 and CO92 Δpgm strains. Survival curves are 
assessed by monitoring the mice twice daily for 15 days. Data is representative of two 
independent experiments (n=7/dose group/experiment).  
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Fig 17: Iron dextran treated B10.T(6R) mice were infected with various strains of Y. 
pestis at LD50 dose (KIM5=14,000 CFU; CO92 = 17 CFUs). Every alternate day post 
infection, sera was collected to measure IL-1β by ELISA. p<0.05 =* p<0.001=*** or ** 
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Fig 18: Neutrophils were sorted and identified as Ly6G+ cells: Neutrophils 
isolated from female B10.T (6R) mouse peritoneal cavity and sorted by flow 
cytometry. Black open square: Unstimulated peritoneal cells from B10.T (6R) mice. 
Red open square: 3% thioglycollate stimulated peritoneal cells from B10.T (6R) mice. 
Y-axis: neutrophil cell count. 	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Fig 19: Iron dextran treated neutrophils isolated from B10.T (6R) mice showed 
lower ROS activity. Neutrophils were infected with Y. pestis KIM5 or CO92 at MOI of 
10. ROS activity was measured using a fluorometric plate reader (Bio Tek) at 480nm/530 
nm.  
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CHAPTER V 
HUMORAL IMMUNE RESPONSE TO YERSINIA PESTIS 
Introduction 
Yersinia pestis, the etiological agent of plague possess virulence factors encoded on the 
chromosome and three plasmids; pCD1, pMT1 and pPCP1. The pMT1 and pPCP1 
plasmid are unique to Y. pestis whereas the pCD1 plasmid is present in all three 
pathogenic strains of Yersinia. The pCD1 plasmid encodes V antigen (LcrV) and a group 
of conserved Yersinia outer proteins (Yops), which is essential for virulence in Y. pestis.  
Yops and V antigen are expressed maximally by Y. pestis at 37°C either in vitro 
conditions under low calcium conditions or when in contact with mammalian cells. The 
effector molecules Yops secreted by the T3SS are secreted into the cytosol of eukaryotic 
host cells, which then subverts the innate immune response. YopH, a tyrosine 
phosphatase, disrupts the link between focal adhesions and actin cytoskeleton; YopT, a 
cysteine protease; YopM, inhibits cysteine protease caspase-1 and helps in depletion of 
natural killer (NK) cells; YopE indirectly depolymerizes actin microfilaments; and YopB, 
YopD, YopK and YopN helps in controlling translocation of Yops to the cytosol of 
eukaryotic host cell. LcrV is involved in resistance to phagocytosis. The pMT1 is a 100 
kb plasmid that encodes the murine toxin and the F1 capsular antigen. The pPCP1 is a 10 
kb plasmid that encodes the bacteriocin, pesticin, and a plasminogen activator protease 
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(Pla) necessary for virulence from subcutaneous route of infection. Other virulence 
factors are the chromosomally encoded pH 6 antigen and lipopolysaccharide (LPS). 
          Diagnosis of human plague infections mostly involves immune responses to F1 
antigen. Animal infection studies have identified several antigens: F1 antigen and LcrV 
protein. Animals actively or passively immunized with F1 or LcrV antigen has shown to 
be protective against pneumonic plague (7). Whole cell vaccines such as Cutter USP and 
EV76 were used to vaccinate humans. Due to safety concerns, both of these vaccinations 
have been discontinued (227). After live attenuated and whole cell vaccines were found 
to have significant limitations, a combinatorial subunit vaccine was developed that 
includes F1 and V antigens of Y. pestis (227). The immunogenic properties conferred by 
the F1/V subunit vaccine and production of IgG1 antibodies was demonstrated by human 
phase I trials. These studies correlate with resistance against Y. pestis infection (252, 
253). There are potential problems associated with F1/V subunit vaccine due to the 
occurrence of naturally occurring F1- strains, which are fully virulent in human infection. 
The F1 protein portion of the vaccine would not be able to provide any defense against an 
F1- strain of Y. pestis. Another problem of the subunit vaccine is the immunosuppressive 
property of the V antigen, as V antigen induces IL-10 production, which suppresses the 
inflammatory immune response to Y. pestis (59). The needle structure of T3SS YscF 
provide partial protection against Y. pestis infection and activates a robust IgG1 
suggesting the inclusion of YscF into F1/V subunit vaccine.  
 Previously in our lab we have shown that young B10.T (6R) mice were resistant to Y. 
pestis KIM5 and this resistance decreases with age (124). The LD50 observed in young 
female B10.T (6R) mice was 14,000 CFUs whereas the LD50 observed in susceptible 
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female C57BL/6J mice were 20-50 CFUs. Here we evaluate whether the presence of 
Yersinia antibodies that are present in resistant B10.T (6R) mice but not susceptible 
C57BL/6J mice accounts for the survivability of the resistant mice post reinfection. 
Young B10.T(6R) mice and C57BL/6J mice were infected with the LD50 dose of Y. pestis 
KIM5 (14,000 CFUs for B10.T(6R) and 40 CFUs for C57BL/6J). Subsequently, after 6 
months, mice that survived the LD50 dose of Y. pestis were reinfected and sera was 
collected and used to evaluate the humoral immune response. We observed that 
antibodies to YopH, YopM, YopB and F1 were found in the resistant mice compared to 
the susceptible mice. 
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Materials And Methods 
Mice 
All mice were housed and bred in Center for Biological Research (CBR), at the 
University of North Dakota. Inbred B10.T (6R) mice were a gift from Dr. Chella David, 
Mayo Clinic and College of Medicine, Rochester, MN. Female B10.T (6R) Female 
C57BL/6 mice were bred at CBR at University of North Dakota. Mice were between 6-8 
weeks of age when challenged with Y. pestis for the studies discussed here.   
Bacterial strains utilized 
All of the bacterial strains (Table 3) were grown in TMH overnight at 26°C, subcultured 
into fresh TMH medium to an A620 of 0.1 and grown until the A620 reached 0.2. The 
temperature was shifted to 37°C and incubated for 6 h while taking A620 reading at 1 h 
intervals. 1 ml of sample was taken into 1.5 ml micro-centrifuge tubes, centrifuged at 
20,000 X g for 5 min at 4°C, pellets contained the secreted proteins. The pellet was 
precipitated with 10% (w/v) trichloro acetic acid (TCA) and proteins were separated 
followed by sodium dodecyl sulfate (SDS) polyacrylamide gel electrophoresis (PAGE). 
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Table 3: Y. pestis strains Utilized 
Bacterial Strains Source 
Y. pestis  
 
KIM8, pCD1-, pla- 
 
Lab stock  
KIM8-3002.1, pCD1 ΔyopB [8-388](Lcr+) pMT1 pPCP1- (213) 
KIM8-3002.8, pCD1 ΔlcrGV2 [LcrGΔ6-95] [LcrVΔ1-268] 
KIM8-3002 Δcaf1  
KIM8-3002 yopK::res 
                       (76) 
 
Lab stock 
 
Lab stock 
KIM8-3002yopH::res Lab stock 
KIM8-3002yopE::res Lab stock 
KIM8-3002yopJ::res Lab stock 
KIM8-3002yopT::res Lab stock 
KIM8-3002yopM:: res Lab stock 
KIM8-3002 ypkA:: res::kan::res Lab stock 
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Bacterial Challenge 
Young B10.T (6R) and C57BL/6 mice were infected with Y. pestis KIM5 intravenously. 
All strains were grown at 26˚C with shaking overnight in Heart Infusion broth (HIB; BD 
Difco) followed by subculture to 0.1 A620, and incubated at 26˚C with shaking to an A620 
of 1.0. Bacteria were centrifuged at 3,220 X g for 5 min, washed twice in sterile 
phosphate buffered saline (PBS) and resuspended in PBS. Mice were monitored twice 
daily for survival for 21 days. The challenge inoculums were LD50 doses: 14000 CFUs 
for B10.T(6R) mice and 40 CFUs for C57BL/6 mice. The serial dilutions used for 
infection were plated on TBA (BD Difco, Sparks, MD) plates and colonies were counted 
after 2 d of incubation at 26˚C. 
Mice that survived the first dose of infection were re-challenged after 6 months with 
lethal doses of Y. pestis KIM5 14000 CFUs for B10.T(6R) mice and 2,000 (100 LD50 for 
C57BL/6J) CFUs for C57BL/6 mice. Sera were collected at d1, d3, d5, and d7 for anti-
Yersinia antibodies. 
Western Blotting 
Proteins were separated by SDS-polyacrylamide gel electrophoresis using 12.5% (wt/vol) 
polyacrylamide gels. Samples were boiled for 10 min prior to loading the gels. The 
proteins were transferred to Immobolin-P membrane (Millipore Corp, Bellercia,MA) 
utilizing carbonate buffer (pH-9.9). Primary antibody (sera from resistant and susceptible 
mice) was added to a dilution of 1:1000. The membranes were washed and secondary 
antibody alkaline phosphatase conjugated anti mouse IgG was used to observe proteins 
by development with nitroblue tetrazolium and 5- bromo-4-chloro-3-indolyphosphate 
(NBT-BCIP, Fisher Scientific, Fair Lawn, NJ) 
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Results 
To identify some Y. pestis virulence determinants, that are expressed and immunogenic 
during bubonic plague in resistant mice, young B10.T(6R) or C57BL/6J mice were 
infected with Y. pestis KIM5 at a dose of 14,000 CFUs or 40 CFUs respectively. Mice 
that survived the LD50 dose of Y. pestis were re-infected with lethal doses of Y. pestis 
KIM5. Sera were collected at day 1 and day 5 post reinfection. Convalescent sera from 
B10.T(6R) mice showed higher production of antibodies to YopB, YopH, YopJ, YopM, 
and F1 compared to convalescent sera from C57BL/6J mice. The naïve B10.T(6R) or 
C57BL/6J mice did not show any change in difference in the intensity of bands following 
infection with Y. pestis KIM5. This result suggests that the convalescent sera of resistant 
B10.T (6R) mice contain anti-Yersinia antibodies, which might be important for the 
survival of resistant B10.T (6R) mice following reinfection as they retain the antibodies. 
Discussion 
Previously it was shown that convalescent plague serum recognizes Yops. After plague 
infection with cell extracts from either Y. pseudotuberculosis or Y. enterocolitica (146) as 
the antigen source, human and mouse serum contained antibodies to Lcr plasmid-specific 
proteins of ∼36 and ∼24 kDa. Another study showed that using Y. pseudotuberculosis 
extracts as the antigen source, Y. pestis infected guinea pigs had an immune response to 
F1 and to plasmid-specific antigens with molecular masses of 76, 41, and 34 kDa, (180). 
Moreover, human convalescent serum from plague patients contains antibodies to YopM 
and V antigen (171). Most of the human cases sera were obtained from human cases of 
bubonic plague resulting from flea-bite, while our studies used mice that recovered from 
intravenously (lethal doses) challenged Y. pestis infection. Y. enterocolitica infected rats 
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make antibodies to V antigen, YopM, and YopH, and also to YopD and YopE, while 
antibody to V antigen and YopH was observed in Y. enterocolitica infected rabbits (73). 
Since most of the antigens analyzed are required for full virulence of the organism by the 
subcutaneous or systemic route of inoculation, we think the results obtained here will be 
similar to those seen after infection from natural routes.  
In our study, the greatest magnitude in antibody responses were seen in resistant B10.T 
(6R) mice compared to C57BL/6J mice. In addition to F1, the antigens that induced 
significant antibody responses are V antigen, YpkA, YopB, YopJ, and YopM, all 
encoded on the Lcr plasmid, which is in accordance with various studies (73, 147, 171). 
V antigen is a protective antigen as shown in both active and passive immunization 
studies. Suppression of pro inflammatory cytokines TNF-α and IFN-ϒ by V antigen also 
supports the idea that V antigen is secreted in vivo (27). YpkA, YopJ and YopM are 
critical for full virulence of Yersinia pestis. (54, 117, 171, 183). These effector proteins 
are translocated to the host target cell cytoplasm in in vitro models. However, YopM also 
functions extra-cellularly. Therefore, it is noteworthy that an immune response was 
generated to YopM. Also antibodies to YopB were generated, and it is known that YopB 
along with YopD, YopN, and YopK, is involved in the translocation of other Yops in 
Yersinia species (53, 228) to the host cytosol. These studies suggest that YopB is 
expressed in vivo, which induces an immune response generating antibodies in vivo. A 
lower magnitude in antibody response to YopH observed in our study (both in the sera of 
resistant B10.T(6R) and susceptible C57BL/6J mice), compared to the findings in rabbits 
(73), may be due to the differences in the route of infection, as we used an intravenous 
challenge model whereas studies performed with rabbits used an orogastric route of 
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infection and with a different species of Yersinia (73). Another reason may be that some 
antigens are differentially expressed (146). 
The antigens that elicited minimal or no antibody responses post re-challenge may be due 
to a number of reasons. Firstly, proteins might be expressed in vivo but at sub 
immunogenic amount thus not inducing an immune response. Another possibility might 
be antigen-presenting cells are not available to the proteins, either because the proteins 
are located intra-cellularly or they are translocated directly by intimate cell contact from 
the bacteria to the host cytoplasm, hence no humoral immune response is generated. 
Lastly, the observed lack of antibody response to some antigens may be due to the assay 
method. An immune response may have been generated but it was below the limit of 
detection, hence could not be identified by immunoblot analysis. Additionally, the 
antigenic preparations used in this study were not in their native conformation hence we 
would not detect antibodies to conformational epitopes of the native protein.  
Our results also suggest that resistant B10.T (6R) mice had a higher magnitude antibody 
response than C57BL/6J susceptible mice, which might attribute to the survival of B10.T 
(6R) mice post reinfection. This study suggests that humoral immune response to plague 
is an integral factor contributing to the resistance mechanism observed in B10.T (6R) 
mice. Analyzing IgG antibody response to the antigens used in this study both in acute 
and convalescent sera from plague infected mice and comparing that with Yersinia 
infected human cell lines would give an insight into understanding the mechanism of 
humoral immune responses to plague. 
 
	   98	  
  
 
 
 
 
 
 
 
Figure 20: Convalescent sera of KIM5 infected B10.T (6R) mice (A-C) and 
C57BL/6 mice (D-F). Lanes; 1: D27x, 2: F1, 3:LcrVG, 4: YopB, 5:YopK, 6:YopH, 
7:YopE, 8:YopJ, 9:YopT, 10: YopM, 11:YpkA. B10.T (6R) mice showed increased 
antibody response than C57BL/6 mice post reinfection with Y. pestis KIM5. (A) and 
(D) Convalescent sera, (B) and (E) day 1 post reinfection, (C) and (F)  day 5 post 
reinfection 	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CHAPTER VI 
DISCUSSION 
Throughout evolution pathogens have developed numerous mechanisms to evade 
the host immune response. For a pathogen to infect and cause disease in a host, the 
pathogen must not elicit a pro-inflammatory response within the host. The manipulation 
of the host immune response allows the bacteria to grow and multiply while allowing the 
host cells to undergo apoptosis. Therefore, it is necessary to understand the strategy used 
by the bacteria to evade host response and use this knowledge to develop new treatments 
to fight the bacteria by giving the host immune system the advantage. One of the many 
advantages of using the mouse model is their striking resemblance to humans in anatomy, 
physiology and genetics. Over 95% of the mouse genome is similar to human genome, 
hence making mouse models effective tools to study progression of diseases. Inbred 
mouse strains are well characterized, as they are genetically uniform enabling 
reproducible studies. Because each inbred strain possesses unique combinations of 
phenotypes and alleles, some strains are susceptible to specific diseases whereas others 
are resistant. Sub strains of inbred 129 mice are highly resistant to infections with the 
KIM5 strain of Y. pestis (48, 230) whereas BALB/c or C57BL/6J strains of mice are 
susceptible to plague infection. The number of bacteria in the organs of 129 mice was 10- 
to 100- fold less than susceptible B6 mice. Resistance to 129 mice 
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is located on the DNA segment near the IL-10 gene  (230).This resistance was not due to 
the presence of a functional Nramp1 (Slc11a1) protein. Nramp1 has been associated with 
resistance to a number of intracellular pathogens and functions as a macrophage and 
neutrophil cationic transporter. Susceptibility to infection has been linked to mutations in 
nramp1 (144). Whether B10.T (6R) mice possess a functional Nramp1 protein and is 
associated with resistance is not clear. However, resistance was not increased to plague 
due to the presence of Nramp1 on a C57BL/6J mice (230). Moreover our model also 
shows that young B10.T (6R) mice are resistant to Y. pestis KIM5 but susceptible to Y. 
pestis CO92 Δpgm. Therefore, it is unlikely that Nramp1 protein influences plague 
resistance in our model.  
The difference in resistance and susceptibility observed in young B10.T(6R) mice 
is not due to the genetic background of the mouse but due to the difference in Y. pestis 
strains. KIM5 is a Mediavalis strain whereas CO92 is an Orientalis strain. One of the 
other differences between the strains is in YopJ effector proteins secreted by the T3SS. 
The YopJ isoform in Y. pestis KIM5 has two amino-acid substitutions, F177L and 
K206E, which are not present in YopJ proteins of Y.pestis CO92 (264). We have shown 
that YopJ was responsible for the difference in outcome of infection in B10.T (6R) mice. 
A set of mutants expressing different isoforms of YopJ confirmed that the difference in 
amino acid was largely responsible for increased virulence of the pandemic strain, CO92 
in the B10.T (6R) mice.    
YopJ is a T3SS effector protein with acetyl-transferase activity that binds with 
MAPK kinases (MKKs) and inhibitor of kappa B kinase beta (IKKβ) (163). The YopJ 
from Y. pestis KIM5 is a distinct isoform with an increased ability to bind IKKβ (264). 
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This leads to higher levels of IL-1β release and increased caspase-1 activation, compared 
to other YopJ isoforms.  
In vivo and comparative analysis provided insight into the differences in virulence 
observed. The most important finding was elevated levels of IL-1β in the sera of KIM5 
infected B10.T (6R) mice compared to CO92 infected B10.T (6R) mice. A lower level of 
IL-1β production seen in the sera, spleen and liver of CO92 infected B10.T (6R) mice 
suggesting that YopJ expressed in CO92 is immunosuppressive to the host. Also higher 
production of IL-1Ra in the sera of CO92 infected mice suggests that YopJ of CO92 
dampens the immune response. This is in accordance to the findings observed in in vitro 
studies where YopJKIM triggers caspase-1 activation and which in turn elevates the IL-1β 
levels whereas YopJCO92 suppresses IL-1β activation in bone marrow derived 
macrophages (264). Mutants expressing different isoforms of YopJ showed that YopJCO92 
when expressed in KIM5 strain suppresses IL-1β levels whereas expression of YopJKIM in 
CO92 strain elevated IL-1β levels. IL-6, and RANTES levels were higher in young 
female B10.T (6R) mice when infected with Y. pestis CO92 strain compared to infection 
by KIM5 strain irrespective of the CFUs used. IL-6 down regulate the pro-inflammatory 
response (112, 202) , strongly supporting the importance of the cytokine in both 
recruitment of neutrophil and modulation of the immune response. KIM5 infected B10.T 
(6R) mice exhibited lower levels of IL-6, and this in turn may impact levels of pro-
inflammatory mediators IL-1β. Since the host is thought to succumb to sepsis during the 
late stages of Y. pestis infection (27) and IL-6 is elevated in both clinical and 
experimental models, the elevated levels of IL-6 in CO92 infected B10.T (6R) mice in 
our model may be a result of YopJ-induced sepsis.   
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C57BL/6 mice are resistant to Y. enterocolitica via the intravenous route of infection 
(194). Interestingly, the 129 strains of mice are only moderately resistant to oral infection 
with the attenuated Y. enterocolitica (203). The route of infection is important for the 
progression of the disease. Most of the Y. pestis strains used in the laboratory are 
attenuated. Hence, infection of mice via subcutaneous route with these attenuated strains 
of Y. pestis would not cause any disease. So to mimic the natural route of infection, mice 
can be supplemented with iron and attenuated strains can be used to infect mice 
subcutaneously that mimic the natural route of infection. We observed a lower mean day 
to death (3-4 days) and lower LD50 when Y. pestis infected mice are supplemented with 
iron. Additionally, when neutrophils were infected with KIM5 or CO92Δpgm, there was 
a higher production of ROS level as compared to neutrophils that were treated with iron 
dextran following infection with either the KIM5 or CO92Δpgm strain of Y. pestis. This 
result suggests that suppression of ROS levels might be attributed to iron overload. 
Supplementing the mice with iron suppresses the immune response by lowering the 
recruitment of neutrophils as well ROS production by neutrophils. As a result neutrophils 
are unable to clear the bacteria, resulting in lower LD50.  
     Young female B10.T (6R) mice can also produce a strong humoral immune response 
to plague (29). We have shown that the convalescent sera of resistant B10.T (6R) mice 
showed a higher magnitude in antibody response than susceptible C57BL/6 mice. 
Analysis of IgG antibody response to the antigens used in this study both in acute and 
convalescent sera from plague infected mice and comparing that with Yersinia infected 
human cell lines would give an insight into understanding the mechanism of humoral 
immune responses to plague. 
	   103	  
Conventionally, mast cells (MCs) are regarded as playing a vital role in IgE-
mediated, Th2 response to allergens. Mast cells are distributed in the host-environment 
interface making these cells accessible to various pathogens. Mast cells also contain pre-
formed mediators, which contributes to the early defense of the innate immune response.  
A unique property of MCs is the ability of long-term proliferation after activation.  MC-
deficient mice (C57BL/6 (KitW-v) and WBB6F1 (KitW/KitW-v) have shown to be more 
susceptible to skin infections caused by Pseudomonas aeruginoa (209). MC deficient 
mice showed skin sections >2-fold larger than those of wildtype mice. Also recruitment 
of neutrophil was decreased, along with their ability to clear the bacterial burden from the 
site of infection. The impaired ability of MCs is also observed in Lysteria monocytogenes 
infected MCs depleted mice. In our study we show that depletion of mast cells by anti-c 
kit (ACK2) monoclonal antibody showed increased mortality in anti-c-kit antibody 
treated B10.T (6R) mice indicating that mast cells might play a pivotal role in defense 
against plague. Increased bacterial burden in anti-c-kit treated antibody than PBS treated 
mice demonstrated that mast cell plays an important role in early host defense against Y. 
pestis. The ability to recruit neutrophils to the site of infection by mast cell mediators is 
impaired in ACK2 treated B10.T (6R) mice due to the absence of mast cells. These 
results correlates with other studies showing the role of mast cells in infection and 
validate results obtained lately in mast cell reconstituted W/Wv mice (67).  
The combined studies performed in our laboratory have allowed us to derive a 
working model of resistance to plague in young B10.T (6R) mice. The different findings 
in these studies related to host immune responses against Y. pestis infections provide a 
background for further studies in plague infection. 
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